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The association of cardiovascular risk factors including hypertension, diabetes, 
cholesterol, kidney function, and arterial stiffness with cognitive impairment in older 
adults is a well-studied phenomenon. However, there is considerably less evidence 
relating cardiovascular health specifically to a diagnosis of Mild Cognitive Impairment 
(MCI). As a precursor state of dementia, MCI is characterized by a decline in cognitive 
function from previous level, but not to the degree that activities of daily living are 
impaired. Not everyone who is diagnosed with MCI will eventually transition to 
dementia, but the transition rates are much higher compared to the general population 
(5-15% per year compared to 1-2%). The primary aim of the current investigation is to 
examine the relationship between individual cardiovascular risk factors and 5-year 
incident MCI risk and to investigate whether these relationships are moderated by 
apolipoprotein E genotype (APOE). An additional primary aim was to investigate 
whether an aggregation count of cardiovascular risk factors (MSLS-CVRFS) and two 
common cardiovascular risk factor profiles (FRS and ASCVD risk score) were related to 
5-year incident MCI risk. Following exclusions for dementia, the study sample included 
625 (Average baseline age: 61.98, 61% female) participants from the 6th and 7th waves 
of the Maine-Syracuse Longitudinal Study (MSLS). MCI diagnosis was made by a team 
of three investigators applying established MCI diagnostic criteria, with 96 participants 
diagnosed with possible MCI. Multiple logistic regression analysis was used to examine 
the association between individual baseline cardiovascular risk factors (SBP, TC, HDL, 
LDL, TRIG, GFR, THCY, Diabetes, PWV) and MCI with adjustment for basic 
demographic covariates including age, sex, years of education, and ethnicity. The same 
method was used for determining APOE interaction effects and relating cardiovascular 
risk factor scores (CVRFS, FRS, ASCVD) with MCI risk. Among individual risk factors, 
higher GFR and HDL were associated with lower MCI risk, while diabetes was 
associated with higher MCI risk. No APOE interaction effects were observed. All three 
of the cardiovascular risk factor scores tested were associated with higher MCI risk.  
These findings have clinical implications with regard to predicting MCI risk with a 
combination of cardiovascular risk factors. While these factors have previously been 
related to continuously distributed cognitive performance measures, it is critical that 
their relationship to a clinically defined binary outcome like MCI be investigated because 
treatment decisions are based on diagnosis.  
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1. INTRODUCTION 
 
1.1. Normal Cognitive Aging  
 
Cognitive changes with age are an expected component of the human lifespan. 
Therefore, it can be difficult to distinguish the pattern of change that can be considered 
“normal” from what can be considered abnormal or pathological in nature. The cognitive 
and functional deficiencies associated with dementia, be it Alzheimer’s disease (AD) or 
Vascular Dementia (VaD), are obvious in comparison to a healthy older adult, but as 
efforts against dementia are increasingly directed towards preventing impairment in the 
first place this comparison is not as helpful anymore. It has become necessary to 
identify cognitive impairment of a pathological nature before extensive functional loss, 
and the concept of Mild Cognitive Impairment (MCI) has arisen to accomplish this. In 
order to investigate MCI, it is important to understand the type and degree of cognitive 
change that one can expect in a healthy, cognitively normal (CN) older adult.  
The concept of crystallized vs fluid intelligence is often a featured component of 
what constitutes normal cognitive aging. Crystallized intelligence refers to long term 
memory related abilities including vocabulary, knowledge, and occupational expertise. 
Fluid intelligence relates more to short term and working memory related abilities 
including novel problem solving, information processing, and psychomotor abilities 
(Harada, Love, & Triebel, 2013; Anstey & Low, 2004). This distinction is often used to 
summarize normal cognitive aging as fluid intelligence is thought to peak around mid-
30s whereas crystallized intelligence is thought to steadily increase throughout the 
lifespan into the 70s (Salthouse, 2012). While helpful, this distinction is somewhat 
simplistic, and the pattern of cognitive decline associated with successful aging free 
2 
 
from pathology is more complex and dependent on additional factors besides age 
alone. 
Going beyond a simple distinction of crystallized vs fluid intelligence, a variety of 
changes are seen in cognition in normal aging. For declarative memory, episodic 
memory is expected to decline with age while semantic memory persists into late life 
(Rönnlund, Nyberg, Bäckman, & Nilsson, 2005). However, non-declarative memory, 
including procedural memory, remains largely unchanged across the lifespan (Lezak, 
Howieson, Bigler, & Tranel, 2012). These memory changes are consistent with other 
studies that have found acquisition (the ability to encode new information) and retrieval 
of recently learned information decline with age (Haaland, Price, & Larue, 2003; Harada 
et al., 2013; Price, Said, & Haaland, 2004) whereas retention of successfully learned 
information in long term memory is maintained (Whiting & Smith, 1997). Likewise, it is 
normal for older adults to decline in tasks involving selective and divided attention, 
although with simple attention tasks no impairment is seen (Salthouse, Fristoe, 
Lineweaver, & Coon, 1995). Reductions in processing speed and executive function are 
also normal, with older adults performing worse at tasks involving mental flexibility, 
response inhibition, inductive reasoning, and abstraction (Lezak et al., 2012; Singh-
Manoux et al., 2012; Wecker, Kramer, Hallam, & Delis, 2005). A variety of other 
cognitive abilities are relatively preserved in normal aging including language skills and 
ability to understand similarities and proverbs (Harada et al., 2013). These changes in 
cognitive abilities refer to averages, but individual differences still play a large role in 
determining whether an individual will experience cognitive decline with age, and what 
degree of impairment will occur.  
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Often degree of impairment (whether normal or abnormal) is subject to individual 
differences in genetics, education, occupation, and culture. These factors, among 
others, have been bundled into a concept known as cognitive reserve, and higher 
cognitive reserve may be protective against deficits associated with normal aging and 
those associated with pathology (Stern, 2002). Education in particular has been 
recognized as an influential predictor of cognitive function in several recent normative 
value publications, including a study of centenarians who are of particular value to the 
study of cognitive aging (Davey et al., 2010; G.A. Dore, Elias, Robbins, Elias, & 
Brennan, 2007). Other experimental studies have reported an effect of education on 
age related cognitive impairment, but the effect may largely depend on the type of 
cognitive ability being measured (Ardila, Ostrosky-Solis, Rosselli, & Gómez, 2000).  
In addition to cognitive performance changes there are identifiable structural 
brain differences in normal aging vs abnormal cognitive aging that may play a causal 
role in observed deficits. For example, hippocampal atrophy is traditionally associated 
with AD, but still occurs in normal aging to a much smaller extent (De Leon et al., 1997). 
Early studies of structural changes in the aging brain likely overestimated the extent of 
neuronal death, with the current thought being that subtle changes involving neuron size 
and synaptic plasticity in key cortical areas may relate to cognitive changes (Morrison & 
Hof, 1997; Terry & Katzman, 2001; Whalley, Deary, Appleton, & Starr, 2004). 
Reductions in gray matter have been reported as early as age in the 20s (Terry & 
Katzman, 2001). The concept of cognitive reserve is supported with structural evidence 
as well, suggesting it may contribute to neural plasticity, larger brain size, and reduced 
neural activity during cognitive tasks, possibly reflecting more efficient resource usage 
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(Solé-Padullés et al., 2009; Whalley et al., 2004). These small structural changes and 
subtle loss of general efficiency among key brain circuits are in sharp contrast to the 
biological changes seen in dementia (See Section 1.3.3.). For further reading regarding 
cognitive aging and accompanying structural changes consult the following resources 
(Park, Denise c.; Reuter-Lorenz, 2012; Raz & Rodrigue, 2006; Salthouse, 1991). 
Ultimately, separating normal cognitive aging from pathological cognitive 
changes can be difficult. However, the changes observed with normal aging are not 
comparable to pathological conditions such as dementia, which includes crippling 
deficiencies in cognitive function and ability to perform activities of daily living (ADLs). 
Normal changes in cognitive function do not compare to even mild degrees of dementia 
(Erkinjuntti, Laaksonen, Sulkava, Syrjalainen, & Palo, 1986). While there are cognitive 
deficits seen in normal cognitive aging, they are of a minor degree and not enough to 
interfere with daily function or social involvement. The idea of pathology with respect to 
cognitive aging should be based on the degree to which the changes interfere with an 
individual’s ability to function independently. However, in terms of dementia this 
introduces a problem. With treatment for dementia increasingly focused on identifying 
prodromal states, it has become necessary to distinguish normal cognitive aging from 
abnormal aging without relying on overt functional impairment in an effort to diagnosis 
and label this prodromal condition. The clinically defined concept of MCI has arisen to 
achieve this, and it represents a likely transitional phase between normal cognition and 
dementia. This pathway between CN, MCI, and Dementia does not exist on the normal 
continuum for cognitive changes with advancing age but rather represents a separate 
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pathway of pathological changes far exceeding those seen in normal aging (See Figure 
1.).  
 
It is of chief epidemiological importance to determine what factors might influence 
whether an individual remains CN with advancing age or diverges to a more sinister 
degree of cognitive impairment, potentially indicative of underlying dementia pathology. 
The current study is focused on the role of cardiovascular risk factors in this divergence 
by focusing on MCI risk. The rationale for this objective is based on the overwhelming 
evidence that cardiovascular risk factors are associated with cognitive performance in 
older age. Therefore, before discussing the conditions of dementia and MCI, and how 
they may relate to cardiovascular health, in the next section we will summarize findings 
suggesting an association between cardiovascular risk factors and cognition assessed 
on a continuum. 
 
Figure 1. Time Course of Dementia with Preclinical MCI Phase 
Note. While some decline in cognitive function is expected with increasing 
age, the changes seen in MCI/Dementia pathology are of a much more 
significant degree. (Sperling et al., 2011) 
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1.2. Cardiovascular Risk Factors and Cognitive Functioning  
 
1.2.1. Hypertension 
 
 The relationship between blood pressure and cognitive functioning has been 
studied extensively, often with conflicting results until the latter half of the 20th century. 
At this time, longitudinal studies began to consistently present evidence associating 
high blood pressure at mid-life with a decline of cognitive functioning in older age (M.F. 
Elias, Goodell, & Dore, 2012; M.F. Elias, Wolf, D’Agostino, Cobb, & White, 1993; Wilkie 
& Eisdorfer, 1971). More recent studies have specifically shown an association between 
elevated midlife blood pressure and increased risk of dementia (Alonso et al., 2009; 
Korf, White, Scheltens, & Launer, 2004; Qiu, Winblad, & Fratiglioni, 2005).  
1.2.2. Arterial Stiffness 
 
 Arteriosclerosis is the progressive hardening of arteries due to age or 
pathological processes such as plaque buildup along the arterial wall (atherosclerosis). 
Compliant arteries are necessary for optimal hemodynamics, allowing the heart to 
supply the body with oxygenated blood with as little impetus as possible (Berne & Levy, 
1986). Stiff arteries reduce this efficiency and create strain on the heart and peripheral 
capillary beds, as well as increasing the risk of thrombosis, emboli, and infarction. 
Severe atherosclerosis is associated with an increased dementia risk and may be 
exacerbated by the Apolipoprotein E ε4 (APOE) allele, discussed further in Section 
1.2.7 (Hofman et al., 1997; Laurin, Masaki, White, & Launer, 2007; van Oijen et al., 
2007). Pulse Wave Velocity (PWV; meters/second) is a recently developed indirect 
measure of arterial stiffness using applanation tonometry that measures the speed of 
the pressure wave generated by heart systole as it travels to the periphery and is 
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reflected back. Several recent studies have associated increased PWV (which reflects 
stiffer arteries) with a decrease in cognitive functioning (M.F. Elias et al., 2009; Wendell, 
Zonderman, Metter, Najjar, & Waldstein, 2009). 
1.2.3. Homocysteine  
 
 Homocysteine is an amino acid normally metabolized by methionine and is 
measured in plasma total homocysteine (tHcy; μmol/L). A high level of tHcy, known as 
hyperhomocysteinemia (HHcy) can cause endothelial cell damage and inflammation, 
gradually deteriorating or hardening blood vessel walls in an arteriosclerotic process 
(Obeid & Herrmann, 2006). Homocysteine levels are heavily influenced by diet choices, 
and diets low in vitamin B6, vitamin B12, folic acid and high in methionine (animal 
proteins) are risk factors for HHcy, as is older age and male sex (Kalra, 2004). The 
inflammatory properties of homocysteine form the basis for the pathology of HHcy as it 
pertains to brain health and dementia. Homocysteine promotes neuronal degeneration, 
particularly of white matter, a consistent target of cerebrovascular pathologies (Obeid & 
Herrmann, 2006). Results from the Framingham Heart Study suggest that individuals 
with a tHcy level over 14 μmol/L have twice the risk of developing Alzheimer’s disease, 
and associate HHcy with smaller brain volume and silent infarctions (Seshadri et al., 
2002, 2008). Numerous other studies have associated elevated levels of tHcy with 
increased dementia risk (Ho et al., 2011; van Dam & van Gool, 2009; Wald, 
Kasturiratne, & Simmonds, 2011).  
1.2.4. Cholesterol  
 
 The relationship between cognitive function and serum lipid levels including Total 
Cholesterol (TC; mmHg), High density lipoprotein (HDL; mmHg), Low density 
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lipoprotein, (LDL; mmHg), and triglycerides (TRIG; mmHg) is controversial. Many 
studies have positively associated TC with cognitive function while others have found a 
negative association. HDL is considered to be a positive factor, whereas TRIG is 
considered to be a negative factor, but results are mixed on these lipid levels as well. 
For a full review of this topic consult (Muldoon & Conklin, 2014).  
1.2.5. Diabetes 
 
 Diabetes mellitus is a significant risk factor for cognitive impairment, and has 
several common cardiovascular comorbidities which can also impair performance 
(Awad, Gagnon, & Messier, 2004; Rodstein, 2001). Commonly affected cognitive 
abilities include attention, memory, processing speed, and executive functioning (Kodl & 
Seaquist, 2008). Further reading on this extensively studied topic is available in several 
recent reviews (Biessels, Deary, & Ryan, 2008; Brands, van den Berg, Biessels, & 
Kessels, 2014). 
1.2.6. Renal Function 
 
 Renal function is a reflection of kidney health and can be represented 
numerically by glomerular filtration rate (GFR), the rate of blood flow through the kidney. 
GFR is estimated through various formulae usually including serum creatinine (a 
metabolic byproduct removed from the blood by the kidneys), age, sex, ethnicity, height, 
and weight. A sustained GFR of less than 60 mL/min is usually a cut-off associated with 
chronic kidney disease (CKD), which has been negatively associated with cognitive 
function in early and late stages of CKD (Brady et al., 2009; Elias et al., 2009). Kidney 
function is usually dichotomized into CKD or non-CKD based on GFR cut-offs when 
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studied in association with cognitive function (Buchman et al., 2009; Elias et al., 2009; 
Kurella-tamura et al., 2009). 
1.2.7. Apolipoprotein E Genotype 
 
 Apolipoprotein E (APOE) is a metabolic protein linked to cognitive impairment 
based on the alleles of the corresponding chromosome 19 gene APOE. Specifically, the 
presence of at least one ε4 allele (APOE ε4 carrier) is a risk factor for cardiovascular 
disease, dementia, and impaired cognitive function (Farrer et al., 1997; Small, Rosnick, 
Fratiglioni, & Bäckman, 2004). APOE ε4 carrier status has also been shown to interact 
with other risk factors, including diabetes, potentially exacerbating cognitive impairment 
(G. A. Dore, Elias, Robbins, Elias, & Nagy, 2009; M. N. Haan, Shemanski, Jagust, 
Manolio, & Kuller, 1999). Aside from considering APOE genotype a risk factor for 
cognitive impairment, its interaction with other cardiovascular risk factors needs to be 
considered.  
1.3. Dementia  
 
1.3.1. Overview 
 
Dementia can refer to a large number of debilitating diseases that can 
compromise an individual’s cognitive functioning, personality, social functioning, and 
ability to live independently. It is a highly heterogeneous condition resulting from several 
different pathologies, and most often combinations of pathologies. While the most 
common form is presumed to be Alzheimer’s disease (AD), other forms include 
Vascular Dementia (VaD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementia 
(FTD). Dementia can be accompanied by a variety of comorbidities including 
Parkinson’s disease and Huntington’s disease. As worldwide life expectancies get 
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longer, these aging-related diseases have been increasing in prevalence and are 
quickly becoming a leading healthcare crisis in the 21st century. Almost 50 million 
people worldwide are estimated to have some form of dementia, with a projected 8 
million new cases each year (World Health Organization). In 2010 worldwide dementia 
costs were estimated to be $604 billion, about 1% of world gross domestic product, an 
enormous cost considering prevalence rates are expected to triple by 2050 (World 
Health Organization). This increase in dementia prevalence will have devastating social 
and economic repercussions, and considering the lack of effective treatment or 
prevention techniques requires immediate attention as a worldwide research priority. 
1.3.2. Diagnosis 
 
 Diagnosing dementia usually involves detecting a clinically significant decline in 
cognitive function from a previous level, to the extent that the patient can no longer 
function independently or perform activities of daily living (ADLs; getting dressed, 
personal hygiene, going shopping etc.). While episodic memory impairment is a 
common cognitive deficit, particularly in the early stages of AD, other deficits in 
cognitive domains including language, attention, executive functioning, working 
memory, and visual-spatial reasoning are possible. Biomarkers and neuropathology are 
becoming an increasingly important part of any dementia diagnosis, taking into account 
the variety of etiologies responsible for the condition. For example, detection of amyloid 
markers in the brain or cerebrospinal fluid (CSF) is now an important diagnostic aspect 
of AD, while cerebrovascular disease or the presence of cerebrovascular risk factors is 
a required part of most VaD diagnoses. Other dementia pathologies such as DLB and 
FTD are different and can result in various clinical phenotypes, but will not be discussed 
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in this study. Mixed etiologies are probably the most common cause of dementia, as 
vascular insults and vascular cascade have been shown to accompany AD pathology, 
resulting in patients exhibiting deficits characteristic of both AD and VaD (Jellinger & 
Attems, 2007; D. S. Knopman, 2006).  
1.3.3. Pathology 
 
1.3.3.1. Alzheimer’s Pathology 
 
 Alzheimer’s pathology is relatively well documented and consistent across cases 
with a general worsening of symptoms and pathology from onset until death. The two 
hallmark signs of the disease are intracellular neurofibrillary tangles composed of 
hyperphosphorylated tau protein (a microtubule associated protein) and extracellular 
neuritic plaques formed by depositions of beta amyloid (Aβ). Neuronal atrophy is also 
common, particularly in the medial and temporal lobes, including the hippocampus. 
These regions are often the first affected by AD pathology and are likely associated with 
primary memory deficits in AD patients. As the disease progresses these pathologies 
can spread to other regions such as the frontal cortex, and cognitive functioning 
progressively worsens as a result of widespread synaptic death.  
While a causal role for any of these biomarkers has yet to be established, their 
presence has become an integral factor in the diagnosis of AD, particularly amyloid 
plaques, which are required for diagnosis. Traditionally this has resulted in tiers of AD 
diagnosis denoted as possible, probable, and definite, the latter only possible with post-
mortem evidence of AD pathology at autopsy. However, improved AD biomarker 
detection via neuroimaging and spinal taps for cerebrospinal fluid (CSF) have aided pre-
mortem diagnoses. Magnetic-Resonance-Imaging (MRI) is useful for detecting areas of 
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structural atrophy. Positron emission tomography (PET) has proven invaluable in the 
detection of AD brain pathology. PET scans using Pittsburgh compound B (PiB) reliably 
detect amyloid plaque deposits in a full brain scan. Fluorodeoxyglucose (FDG) PET 
scans assess glucose metabolism across the brain, and can be used to check for 
hypometabolism in certain areas, particularly the medial and temporal lobes when 
assessing AD pathology.  
1.3.3.2. Vascular Pathology 
 
 Vascular Dementia pathology is considerably more heterogeneous than AD 
pathology because it can be caused by any combination of cerebrovascular diseases 
with varying severity. Consequently, symptoms and prognosis can be more varied 
depending on the location and severity of the vascular insult. Stroke is perhaps the most 
obvious cerebrovascular event that could contribute to cognitive impairments of a 
dementia degree. However, other smaller vessel diseases are possible and over time 
can be just as impactful. Small vessel diseases are estimated to have a causal role in 
40-70% of VaD cases  (Román, 2003). These include lacunar infarctions (which are 
often asymptomatic), cerebral microbleeds, and leukoaraiosis. Small infarctions are 
localized tissue death due to an obstruction of normal blood flow to the area and are not 
necessarily uncommon. The prevalence of silent infarctions is about 20% in the normal 
population but as high as 50% in those with vascular disease (Longstreth et al., 2005). 
Silent infarctions are associated with a doubled risk of vascular cognitive impairment or 
dementia over a five year period (Longstreth et al., 2005). Leukoaraiosis is represented 
by white matter hyperintensities (WMH) on T2 weighted MRI images demonstrating the 
destruction of white matter tracts in the brain. This white matter damage is thought to be 
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associated with vascular mechanisms and is associated with typical cardiovascular risk 
factors including hypertension and diabetes, and may play a causal role in cognitive 
deficits seen in VaD. 
1.3.3.3. Mixed Pathology 
 
 Dementia and MCI rarely fit into neat diagnostic paradigms perfectly describing 
the underlying pathology. The prevalence of mixed pathology both in dementia and MCI 
has been increasingly recognized, with some studies claiming a mix of AD and vascular 
pathology may account for the near-majority of dementia cases at around 40% (Price, 
Nguyen, Lamar, & Libon 2015; Lockhart and DeCarli 2015). VaD and AD pathology 
have considerable co-occurrence, with some going so far as to claim “Pure VaD” and 
“Pure AD” as rare (Jellinger & Attems, 2007). There is often a vascular component to 
AD, and unfortunately the two pathologies have a “complementary and synergistic 
relationship in the genesis of cognitive impairment” (D. S. Knopman, 2006). Growing 
evidence suggests that AD and vascular pathology may be additive in that individuals 
with mild AD or cerebrovascular pathology are less likely to progress to dementia than 
individuals with both (Fotuhi, Hachinski, & Whitehouse, 2009; Nagy et al., 1997; 
Schneider, Arvanitakis, Bang, & Bennett, 2007; Snowdon et al., 1997; Viswanathan, 
Rocca, & Tzourio, 2009). 
 The degree to which dementia varies in terms of mixed etiologies is not 
surprising considering that AD and VaD share several common risk factors, including 
cardiovascular risk factors. Mixed pathologies complicate differential dementia 
diagnosis because the brain areas effected can vary considerably from the common 
parietal-temporal damage seen in AD to the subcortical white matter damage often 
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observed in VaD. This may be the case for MCI diagnosis as well if this condition truly 
reflects early stages of the pathology seen in fully developed dementia. Cardiovascular 
risk factors may contribute to both AD and VaD pathology and both of these etiologies 
need to be considered when discussing preventive interventions and post-diagnosis 
treatments.  
1.3.4. Prodromal State  
 
 Current efforts regarding the treatment of dementia are increasingly focused on 
prevention. This emphasis has resulted in increased attention to identifying prodromal 
states of dementia. While many states have been proposed and defined, the concept of 
MCI has emerged as an important clinical state in the progression of dementia 
pathology. MCI is an age associated decline in cognitive functioning from normal levels 
that does not meet thresholds for dementia diagnosis, nor impair the individual’s daily 
functioning. While diagnoses and operational definitions for MCI vary, all agree that MCI 
is a clinically relevant category of cognition that represents a risk factor for progression 
to dementia. Identifying individuals presenting with MCI provides an opportunity for early 
preventative interventions to slow the progression to dementia or ideally stop it 
altogether, though a delay in transfer from MCI to dementia is the most realistic 
treatment outcome at this time. MCI will be discussed fully in the following section. 
While this study does not deal with intervention it does deal with MCI as primary 
cognitive outcome variable. 
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1.4. Mild Cognitive Impairment  
 
1.4.1. Conceptual Overview  
 
 MCI is a continually developing clinical concept intended to represent a 
transitional period between normal cognitive functioning with age and dementia states. 
Figure 1. illustrates this concept as a transitional period between normal function and 
dementia, with a preclinical period predating the onset of MCI (Sperling et al., 2011). 
The concept originates from early longitudinal studies on aging and dementia, in which 
large groups of subjects appeared to fit in intermediate stages that could not be defined 
as normal or demented (Petersen, 2004). From a modern perspective this degree of 
impairment was originally defined as an intermediate stage of impairment based on the 
Global Deterioration Scale (Reisberg, Ferris, De Leon, & Crook, 1988). From this point, 
the concept has evolved under several names including benign senescence 
forgetfulness, age-associated memory impairment (AAMI), age-associated cognitive 
decline (AACD) and cognitive impairment no Dementia (CIND), although there has been 
considerable overlap between all of these systems of description and diagnosis (R. C. 
Petersen, 2004). The important and widely agreed upon characteristics of MCI are as 
follows: 1.) Person has an impairment in one or more cognitive domains that reflects a 
decline from previous function, 2.) Person has largely preserved independence and 
every day functioning and can perform activities of daily living (ADL) with little to no 
assistance, 3.) Person is not demented. How these characteristics are defined and 
measured, in addition to whether or not requiring corroboration by an informant 
(typically a family member), varies considerably. Moreover, meeting criterion two 
eliminates the possibility of meeting criterion 3 in most of these systematic approaches.  
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 MCI represents a subtle continuum between what is considered normal cognitive 
aging and pathological impairment due to dementia, and this creates what is referred to 
as an ambiguous ‘grey zone’ with considerable overlap on either side of the continuum 
(Feldman & Jacova, 2005; Petersen, Smith, & Waring, 1999). See Figure 2. for a 
representation of this continuum and note the overlap on both sides of the period 
commonly defined as ‘MCI’. The lack of clinical consensus in the field for defining this 
period comes from several different sources, including but not limited to varying 
diagnostic tools such as cognitive assessment measures, differences in populations 
(e.g., community-based samples vs clinic referral samples), and perhaps most of all the 
several etiologies and pathology proposed to be behind MCI, which may vary as much 
as dementia etiology does (Petersen et al., 2014; Stephan et al., 2012). This has led to 
considerable variability in diagnosis and conceptualization of this important clinical 
period. 
 
 
 
 
 
 
 
 
 
Normal 
MCI 
Dementia 
Worsening Cognitive Performance 
Figure 2. Continuum of Cognitive Performance from Normal to MCI to Dementia 
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1.4.2. Diagnosis 
 
 Diagnostic criteria for MCI have evolved via several nuanced changes and 
categorizations over the past two decades, but the fundamental Mayo Clinic criteria laid 
out by Petersen et al. in 2004 are still essential. Petersen laid out 5 defining 
characteristics of MCI, and while these are adjusted somewhat by other diagnostic 
criteria (Diagnostic and Statistical Manual of Mental Disorders V (DSM-V), National 
Institute on Aging-Alzheimer’s Association (NIA-AA) etc.) the general principles are 
largely the same. These original criteria are outlined in Table 1., along with recent 
revised criteria. One may note that these criteria are focused specifically on memory 
impairment as this was thought to be the most common form of MCI, and the form most 
likely to predict AD (Petersen et al., 2014). These criteria are still relevant today but now 
represent a common MCI subtype referred to as Amnestic MCI or a-MCI (Petersen et 
al., 2014; Petersen, 2011). 
 
 The biggest shift in MCI diagnosis in recent years has been the adoption of 
multiple subtypes of MCI to reflect the variety of clinical phenotypes commonly seen. 
Diagnostic criteria have accounted for this by specifying the term ‘cognitive impairment’, 
Table 1. Mayo Clinic MCI Criteria Original and Expanded 
Criteria 
Original  
Mayo 
Clinic 
Revised/ 
Expanded 
Reported Memory Impairment (Self or Informant) ✓  
Reported Cognitive Impairment (Self or Informant)  ✓ 
Objective Memory Impairment  
(Neuropsychological testing) 
✓  
Objective Cognitive Impairment  
(Neuropsychological testing) 
 ✓ 
Preserved general cognitive function ✓  
Preserved functional independence and ADLs ✓ ✓ 
No dementia ✓ ✓ 
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with more sensitivity to type of impairment, primarily involving memory or not. Revised 
Mayo criteria, in addition to NIA-AA criteria for MCI and DSM-V criteria for Mild 
Neurocognitive Disorder (NCD), now allow for cognitive impairment to reflect any 
cognitive domain, not just memory impairment (Petersen et al., 2014; Petersen, 2011). 
In recognition that multiple cognitive domains can be impaired in the same case, four 
major MCI subtypes have arisen to reflect different cognitive profiles. The four subtypes 
reflect two values: whether or not the individual has a memory impairment (amnestic or 
non-amnestic) and whether or not the individual has impairment in multiple cognitive 
domains (single domain or multi-domain). Therefore the current MCI subtypes are 
amnestic MCI single domain, amnestic MCI multi-domain, non-amnestic MCI single 
domain, and non-amnestic MCI multi-domain. Reliable prevalence rates for these 
subtypes have not been established at this time, though non-amnestic single domain 
MCI is considered rare (Petersen, 2004). It is important to recognize that these MCI 
subtypes do not reliably represent etiology of the condition and pertain only to clinical 
phenotype. The various brain pathologies though to be responsible for MCI and 
dementia have not been accurately mapped on to these diagnoses, though there is 
growing evidence that amnestic forms of MCI may be associated with AD pathology 
whereas non-amnestic forms may represent non-AD dementia pathologies including 
cerebrovascular disease (Feldman & Jacova, 2005; R. Petersen, Thomas, & M, 2005; 
Stephan et al., 2012). 
 While the essential aspects of cognitive impairment in MCI are becoming more 
established, there is little consensus in the field regarding specific tests or assessments, 
as well as corresponding cut-off scores, for use in diagnosing MCI. Larger scale 
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neuropsychological batteries provide a detailed cognitive profile of patients, but are not 
always practical to use in a clinical setting. Quicker assessments are often used, and 
even amongst these there is great variability in the specific tests used. Common 
assessments used include the Wechsler Adult Intelligence Scale Revised (WAIS-R), 
Wechsler Memory Scale-Revised (WMS-R), The Auditory Verbal Learning Test, The 
Wide Range Achievement Test (WRAT), Controlled Oral Word Associations, and the 
Boston Naming Test. Shorter assessments include the Mini Mental State Exam (MMSE) 
and the Montreal Cognitive Assessment (MOCA), though the MMSE has been criticized 
as not being sensitive enough as a single use measure detecting impairment. Studies 
often use multiple measures to attempt to detect impairment in multiple domains of 
cognitive functioning including memory, executive functioning, attention, language, and 
visuospatial ability. While no specific cutoff scores are agreed upon, it is generally 
considered that impairments ranging from .5-1.5 standard deviation units below age-
based cognitively healthy norms are a good starting point, reflecting performance in the 
31st percentile and lower (Petersen, 2003). However, impairment has to be examined 
considering previous function of the individual, which is more important than arbitrary 
cut-off scores. A change in function is a reliable indicator of possible MCI, and this 
approach is often used in epidemiological studies and retrospective analyses. 
1.4.3 Prevalence and Incidence 
 
 Population statistics for MCI are difficult to determine given the variety of 
acceptable diagnostic criteria for clinical deficit or change from a previous level, and the 
population from which the individuals were sampled. Early epidemiological studies likely 
underestimated the prevalence of MCI in the population because of the memory bias in 
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diagnosis (Petersen et al., 2014). When MCI is rightfully conceptualized as including all 
forms of cognitive impairment prevalence statistics have been higher. In United States 
samples the prevalence of MCI in the 65+ year old population tends to range between 
15-25% (Ganguli et al., 2010; O. Lopez, Jagust, & DeKosky, 2003; Manly et al., 2008; 
R. Petersen, Roberts, & Knopman, 2010; Plassman, Langa, & Fisher, 2008; Purser, 
Fillenbaum, Pieper, & Wallace, 2005). A reliable incidence rate is similarly challenging 
but some aggregate data suggests the rate may range between 20-70 per 1000 person-
years (Petersen et al., 2014; Ward, Arrighi, Michels, & Cedarbaum, 2012). Despite the 
variability in statistics it is clear that MCI is not a rare condition and deserves attention. 
1.4.4. Prognosis and Treatment  
 
 The clinical relevance of MCI depends on its use as a detection of a prodromal 
dementia state that provides the opportunity for early interventions and identification of 
at-risk populations. It is important to note that the prodromal state where MCI is first 
seen is part of the long latency period for dementia, where pathology is emerging in the 
brain but the individual is not yet demented as illustrated in Figure 3. (Sperling et al., 
2011). Regardless of the various definitions and diagnostic procedures, MCI does 
reliably predict an increased risk of dementia as compared to normal cognitive aging. 
MCI is a risk factor for dementia, as it is now clear that lowered cognitive functioning in 
a number of domains predicts dementia many years later. Conversion rates from MCI to 
dementia vary, but are reported around 5-15% per year (Larrieu et al., 2002; Petersen 
et al., 1999; Petersen, 2011). This rate can be compared to an estimated dementia 
conversion rate of 1-2% per year from the general population (Petersen, 2011). Overall, 
several longitudinal studies have supported that MCI is a significant risk factor for 
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dementia and predicts a higher conversion rate, though not everyone with MCI will end 
up progressing to dementia (Busse, Hensel, Guhne, Angermeyer, & Riedel-Heller, 
2006a; O. Lopez et al., 2003; Manly et al., 2008; Plassman et al., 2008). Some studies 
have shown reversal of MCI patients to cognitively normal levels at a rate as high as 
40%, which likely reflects errors related to diagnosis being heavily memory-based in 
earlier approaches and the difficulty of separating normal cognitive aging from MCI 
(Larrieu et al., 2002). 
 Several factors have been studied predicting higher risk of transitioning from MCI 
to dementia. The greater the extent of cognitive impairment of the individual the more 
rapid progression to dementia tends to be (Dickerson, Sperling, Hyman, Albert, & 
Blacker, 2007; Visser, Verhey, & Knol, 2009). The APOE ε4 allele has also been 
Figure 3. Neuropathological Cascade Preceding MCI and Dementia 
Note. The prodromal phase of dementia is a long and dormant process of which MCI is the 
first phase in which cognitive deficits are observable. This example from  (Sperling et al., 
2011) provides a hypothetical model of AD pathology predating MCI and Dementia, likely by 
many years.  
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associated with more rapid progression to dementia (Hsiung, Sadovnick, & Feldman, 
2004; Mosconi et al., 2004). Neuroimaging has supplemented MCI to dementia 
transition risk assessment, but there are conflicting findings. A 2010 study by Jack et al. 
revealed that MCI subjects in the bottom 25% of hippocampal volume (revealed by MRI) 
for sex and age norms had a more rapid progression to dementia. Other AD biomarkers 
and neuropathology have been associated with transition from MCI to AD, including 
hypometabolism in the temporal and parietal lobes on FDG-PET scans (Chetelat et al., 
2003; Drzezga, Grimmer, & Rjemenschneider, 2005; Landau, Harvey, & Madison, 
2010). Cerebrospinal fluid markers of low beta amyloid peptide 42 and tau protein have 
similarly been shown to predict more rapid transition (Hansson et al., 2006), though 
amyloid has been found in cognitively healthy adults (DS Knopman, Parisi, & Salviati, 
2003). The neuropathology of MCI is not well understood at this time, though there is 
some evidence that it may reflect early dementia pathology, which varies widely in 
etiology given the several different forms of dementia (Stephan et al., 2012). 
 Treatment for MCI is currently suboptimal, and pharmacological interventions 
have been challenging given the heterogeneity of the condition. At this time there is no 
FDA approved treatment for MCI (Petersen, 2011). A few clinical trials have taken place 
with largely null results. Donezpil, a cholinesterase inhibitor, failed to reverse cognitive 
decline in an MCI population (Russ & Morling, 2012) and similar results were observed 
for  vitamin E trials (Farina, Isaac, Clark, Rusted, & Tabet, 2012; Petersen et al., 2014). 
Cognitive training has shown limited efficacy but may be a promising avenue for further 
trials (Jean, Bergeron, Thivierge, & Simard, 2010; Massoud, Belleville, & Bergman, 
2007). While modification of cardiovascular risk factors has received mixed results in 
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terms of slowing the progression from MCI to Dementia (Di Carlo, Lamassa, & 
Baldereschi, 2007), there is some evidence that regular aerobic exercise can slow the 
progression significantly (Ahlskog, Geda, Graff-Radford, & Petersen, 2011). Ultimately, 
more clinical trials are necessary, ideally those that combine multiple interventions such 
as cognitive training, healthy lifestyle changes, and medication that are based on as 
much information as possible regarding the etiology of an individual’s MCI.  
1.5. Cardiovascular Risk Factors and MCI 
 
 The relationship between cardiovascular risk factors and cognitive functioning is 
well known as a result of a rich literature base (See Section 1.2.). However, the 
literature base associating cardiovascular risk factors with MCI specifically is much 
sparser. While MCI may be seen as an obvious corollary of continuous cognitive 
function, this important diagnostic entity requires more focused studies in order to 
determine the contribution of cardiovascular risk factors to a clinically defined condition 
of cognitive impairment. Table 2. summarizes some of the most well-cited studies in this 
small but developing literature base. These studies vary in design and follow-up 
periods, but all attempted to associate cardiovascular risk factors with MCI specifically, 
and not continuous cognitive function. To date, the risk factors studied include 
hypertension, coronary artery disease (CAD), stroke, Type II Diabetes, Total 
Cholesterol (TC), High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), 
Triglycerides (TRIG), HCY, APOE Genotype, and vascular brain damage in the form of 
white matter lesions, infarcts, and atrophy. 
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Table 2. Review of Cardiovascular Risk Factors for MCI  
Study Design Risk Factor(s) Results 
(Solfrizzi et 
al., 2004) 
Prospective 
Hypertension, CAD, Stroke, Type 2 Diabetes,  
TC, HDL 
CV Risk factors likely increase the risk of MCI progression to 
dementia, but did not find that these factors predict higher MCI risk 
(Cheng et al., 
2012) 
Meta-
Analysis 
Type 2 Diabetes Higher incidence of MCI in subjects with Diabetes 
(J. A. 
Luchsinger et 
al., 2007) 
Prospective Type 2 Diabetes Diabetes predicts MCI prospectively  
(Faux et al., 
2011) 
Cross-
Sectional 
Homocysteine Hcy did not relate to MCI 
(Kim et al., 
2007) 
Cross-
Sectional 
Homocysteine Hyperhomocysteinemia linked to MCI in an older cohort 
(M Kivipelto 
et al., 2001) 
Prospective 
Hypertension, TC, Antihypertensive medication,  
Type 2 Diabetes 
Midlife SBP and TC predicted MCI, diabetes and antihypertensive  
meds did not 
(O. L. Lopez 
et al., 2003) 
Prospective 
Hypertension, APOE, Vascular brain damage (MRI), 
Stroke, Type 2 Diabetes, Heart Disease 
Hypertension, APOE genotype, MRI evidence of white matter 
lesions/infarcts, diabetes, and heart disease all predicted MCI 
prospectively. Stroke did not predict MCI.  
(Rasquin et 
al., 2004) 
Prospective Stroke 
Stroke predicted MCI at one year follow up but evidence this  
impairment may be reversible  
(Reitz et al., 
2007) 
Prospective Hypertension, APOE  
Hypertension predicted 5 year all cause MCI and non-amnestic MCI,  
but not amnestic MCI. No interaction with APOE genotype.  
(Reitz et al., 
2008) 
Prospective TC, HDL, LDL, TRIG, Lipid-lowering treatments  
No relationship between serum lipid levels and MCI, no effect of  
lipid-lowering treatments on MCI risk  
(Toro et al., 
2014) 
Prospective TC, APOE 
Higher TC predicted MCI over 14 year time period but did  
not interact with APOE 
(D. et al., 
2010) 
Cross 
sectional  
TC (Familial Hypercholesterolemia), APOE 
Familial hypercholesterolemia associated with MCI,  
independent of APOE genotype 
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At present, results associating these risk factors with MCI are somewhat mixed. 
A few of the major studies demonstrated an association between common 
cardiovascular risk factors like hypertension, diabetes, and lipid levels on MCI, but 
others reported no association. Some of these inconsistencies are likely due to 
differences in MCI diagnosis. The literature base is strong enough to warrant further 
study, both in the interest of replication and new hypotheses. There are many gaps in 
the cardiovascular risk factor and MCI framework that can be addressed. No studies 
associating PWV measured arterial stiffness or GFR measured renal function with MCI 
were found. Homocysteine studies have been done and while informative they are 
mostly cross-sectional, resulting in an obvious need for a prospective study of HCY and 
MCI. Furthermore, while APOE genotype has been studied there is a need for more 
testing of interactions between APOE genotype and cardiovascular risk factors. This 
gap coincides with an overall lack of studies that associate the aggregation of multiple 
cardiovascular risk factors, and how they may interact to contribute to MCI risk. This 
study will attempt to address some of the gaps in this literature, as well as replicate 
other findings.  
1.6. Cardiovascular Risk Factor Scales 
 
1.6.1. Cardiovascular Risk Prediction Models 
 
 It is now well known that the combination of multiple cardiovascular risk factors 
can aggregate and contribute to CVD risk (Goff et al., 2014; Piepoli et al., 2016; Yusuf 
et al., 2004). However, it can be difficult to quantify exact risk for a patient who visits his 
or her clinician with a handful of risk factors, some of which may not reach clinically 
established “cut-offs” for what constitutes risk. In an effort to make risk calculation 
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easier for individual patients, various groups from large epidemiological studies on 
cardiovascular health have devised risk models using Cox Regression hazards models 
in  order to identify variables and their individual contribution to risk. Because these 
studies are focused on cardiovascular health, the outcome “event” being predicted by 
these models is usually some degree of first time CVD or specifically first time Coronary 
Heart Disease (CHD). These models are constantly evolving to incorporate new risk 
variables and more data from larger study populations, but there is an emphasis on 
keeping the models as simple as possible for use in a clinic setting to quickly quantify a 
patient’s 10 year risk of CVD/CHD. 
 The basic foundation for many of these cardiovascular risk prediction models 
comes from early attempts by the Framingham Heart Study to quantify CVD Risk 
(Kannel, McGee, & Gordon, 1976). Framingham’s General Cardiovascular Risk score 
has since been refined with additional decades worth of data, and has now been 
adopted to a simple point scoring system that incorporates age, sex, SBP, hypertensive 
medication treatment, TC, HDL, smoking status and diabetes (D’Agostino et al., 2008). 
This Framingham Risk Score (FRS) was developed using cox regression to investigate 
the 12 year risk of a first CVD event using a sample of 8491 Framingham study 
participants. The FRS does very well at predicting various CVD events including CHD, 
Stroke, Intermittent Claudication, and Congestive Heart Failure. The score is useful in 
clinical settings because it is simple and based on fundamental cardiovascular variables 
that would be gathered in relatively routine checks. It has been incorporated into many 
simple online calculators for a quick estimate of 12 year first-time CVD risk. See 
Appendix A for FRS scoring tables adapted from D’Agostino et al. 2008. 
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The FRS is not without critique however, with some research groups pointing to 
its lack of certain factors such as ethnicity, and other risk factors as flaws that can be 
addressed by a more robust risk prediction model. The SCORE project in Europe 
developed as a collaboration between 12 large cohort studies, collectively including 
over 200,000 participants, to devise a risk prediction model for Europeans (Conroy et 
al., 2003). Like the FRS, SCORE includes age, sex, smoker status, TC, HDL, and SBP, 
although age is included not as a risk factor in itself but as a measure of exposure time 
to other risk factors. The model also includes nationality as a risk modifier by identifying 
certain populations as “high-risk” (Russia, Latvia, Georgia etc.) and others as “low-risk” 
(Germany, United Kingdom, Italy etc.). SCORE is somewhat unique in comparison to 
other risk models like Framingham in that it specifically predicts fatal cardiovascular 
events over a 10 year period, and not cardiovascular events based on a clinical 
threshold. Unlike several other risk models, SCORE does not include diabetes due to a 
data limitation in that not all of the included cohort studies had diabetes data (Conroy et 
al., 2003). 
Other models have attempted to include data on risk factors that they felt were 
lacking in Framingham’s original risk scores. For example, the ASSIGN score from the 
Scottish Heart Health Extended Cohort includes family history and social deprivation in 
addition to the traditional FRS risk factors (Woodward, Brindle, & Tunstall-Pedoe, 2007). 
The PROCAM scoring scheme for coronary event risk incorporates family history and 
additional serum lipid levels including LDL and TRIG (Assmann, Cullen, & Schulte, 
2002). The Reynolds Risk Score for women was developed to specifically address the 
large number of coronary events that were occurring in women who did not have the 
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risk factors included in the older Framingham risk models (Buring & Cook, 2007; Khot et 
al., 2003). In their model, based entirely on coronary event risk in women, they included 
additional apolipoproteins, C-Reactive Protein (CRP), and parental history, among other 
factors. In addition to these risk factors, diabetes was conceptualized not 
dichotomously, but as a continuous variable reflecting hemoglobin A1C levels. While the 
inclusion of additional risk factors may seem to create a more inclusive model, they 
complicate the original conception behind cardiovascular risk prediction models in that 
they should be simple and easily applicable in an office setting. Furthermore, there is 
some evidence that the simpler models like FRS and SCORE still outperform more 
complex models like PROCAM in terms of determining absolute CVD risk over the time 
periods they specify (Versteylen, Joosen, Shaw, Narula, & Hofstra, 2011). 
One of the most recent attempts to formulate a CVD risk prediction model that 
includes Framingham’s base risk factors but addresses ethnicity concerns comes from 
a 2014 report from the American College of Cardiology/American Heart Association 
(Goff et al., 2014). This risk model specifically predicts the risk of an arteriosclerotic 
cardiovascular event, including heart attack and stroke, and is abbreviated ASCVD risk 
(arteriosclerotic cardiovascular disease). In an attempt to address a flaw in the FRS, 
primarily that it was based on a predominantly white New-England sample, the ASCVD 
risk score includes a separate risk algorithm for black patients in addition to separate 
algorithms for men/women and hypertensive treatment/no-treatment. Besides these 
additions, the score is still derived from age, TC, HDL, SBP, smoker status, and 
diabetes just like the FRS in an attempt to keep the score based on routinely collected 
data. Other risk factors including DBP, family history, GFR, and BMI were investigated, 
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but they did not significantly improve model discrimination for 10-year ASCVD. Unlike 
the FRS, the ASCVD score has not been adapted to a simple point scoring system but 
is still based on an easily implemented algorithm and can similarly be quickly provided 
by various online calculators. See Appendix B for risk scoring algorithms adapted from 
Goff et al. 2013.  
It is evident that there is a growing number of CVD risk prediction models 
presently in circulation, and this can create a problem for physicians trying to determine 
which model to use in their own patients. A recent review expanded on this issue, 
claiming that the number of risk models currently in use is excessive, and more efforts 
should be made to externally validate existing models using large epidemiological 
datasets rather than create new prediction models (Damen et al., 2016). Aside from the 
FRS and SCORE, very few of the models in circulation have undergone rigorous 
external validation (Damen et al., 2016). Some have suggested that risk prediction 
models are most appropriately used for individuals who resemble the study sample from 
which the model was derived (e.g. FRS for white New-England residents; Wilson et al 
1998). Regardless of the issues of oversaturation of risk models and demographic 
concerns, these models are still extremely useful for predicting CVD events in patients 
who may have multiple marginal risk factors that may not warrant individual treatment 
(D’Agostino et al., 2008; Grundy et al., 1999; Wilson et al.,1998).  
1.6.2. Using Cardiovascular Risk Prediction Models beyond CVD 
 
Section 1.2. established that there is an extensive literature base associating 
cardiovascular risk factors with cognitive function, and Section 1.5. discussed growing 
evidence that cardiovascular risk factors may predict MCI risk. It is possible that an 
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aggregation of cardiovascular risk factors may interact to increase MCI and cognitive 
decline risk in a similar manner to predicting CVD incidence. Current risk models are 
based on specific CVD outcome events like CHD, but they may have some use in 
predicting other conditions like MCI given what is now known about cardiovascular risk 
factors and their ability to predict other conditions outside coronary events alone, 
including dementia (Miia Kivipelto, Ngandu, & Fratiglioni, 2005; J. Luchsinger et al., 
2005; Whitmer, Sidney, Selby, Claiborne Johnston, & Yaffe, 2005). Despite the models 
being tailored for another condition, they are still based on fundamental cardiovascular 
risk factors, and may elucidate the role of these variables in MCI risk. Similar 
approaches have been used to assess the relationship between cardiovascular risk 
profiles and cognitive function, with Framingham’s stroke risk profile shown to predict 
not only stroke risk, but cognitive decline in general (Elias et al., 2004). In some cases it 
has been reported that cardiovascular risk profiles have bested even specifically 
developed dementia risk scores in the prediction of future cognitive impairment 
(Kaffashian et al., 2013).  
1.7. Objectives and Hypotheses  
 
1.7.1. Primary Objectives 
 
 The primary objectives of this study will be to address the current gaps in the 
cardiovascular risk factor and MCI literature using the large community-based sample of 
the Maine Syracuse Longitudinal Study (MSLS). Hypotheses are based on previous 
studies from the MSLS associating cardiovascular risk factors with cognitive 
impairment, as well as the literature reviewed in Section 1.5. speculating an association 
between cardiovascular risk factors with MCI and Dementia. All hypotheses are 
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expected to hold under adjustment for basic model covariates including age, sex, years 
of education, and ethnicity. Primary objectives are as follows: 
1. Determine whether cardiovascular risk factors including SBP, GFR, THCY, Serum 
Lipids (TC, HDL, LDL, TRIG) and Diabetes predict MCI prospectively. Additionally, 
determine whether arterial stiffness associates with MCI cross-sectionally.  
Hypothesis: We predict that higher SBP, THCY, and TRIG will be associated with 
higher MCI risk and that higher MCI risk will be seen is diabetics. We also predict 
that HDL and GFR will be associated with lower prospective MCI risk. No 
relationship between TC and LDL with MCI risk is expected. Finally, we predict 
higher PWV among those categorized as MCI compared to CN.  
2. Determine whether APOE genotype moderates the relationship between the 
cardiovascular risk factors included in this study and MCI. 
Hypothesis: We predict that APOE genotype will moderate the relationships 
predicted in Objective 1 such that the presence of an APOE ε4 will exacerbate 
the direct relationship between SBP, THCY, TRIG, and PWV with MCI, and 
attenuate the inverse relationship between HDL and GFR with MCI.  
3. Determine whether an aggregation of cardiovascular risk factors categorized 
dichotomously into disease/non disease states (hypertension, CKD, diabetes etc.) 
predicts greater MCI risk prospectively. This aggregation is represented in the MSLS 
Cardiovascular Risk Factor Scale (MSLS-CVRFS; See Section 2.5.1. in the Methods).   
Hypothesis: We predict that a higher score on the MSLS-CVRFS will 
prospectively predict greater MCI risk. 
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4. Determine whether existing cardiovascular risk models designed to predict CVD over 
a 10-12 year period also predict MCI risk. The two models tested in this study will be the 
FRS (D’agostino 2008; See Section 2.5.2) and the ASCVD Risk Score (Goff 2013; See 
Section 2.5.3.) 
Hypothesis: We predict that both the FRS and ASCVD Risk score will 
prospectively predict greater MCI risk. 
1.7.2. Secondary Objectives 
 
 Secondary objectives of this study involve supplementary analyses related to the 
findings of the above primary objectives. 
1. Compare the three cardiovascular risk scales used in this study (CVRFS, FRS, and 
ASCVD Risk Score) in their ability to predict MCI.  
Hypothesis: While we expect that all three scales will predict higher MCI risk, we 
predict that the FRS and ASCVD Risk Scores will perform similarly and both 
outperform the CVRFS. The rationale for this hypothesis is based on the fact that 
the FRS and ASCVD Risk Score include critical demographic information 
including age, sex, education whereas the CVRFS is based composed only of 
cardiovascular variables.  
2. Determine whether the CVRFS prospectively predicts cognitive performance 
measured on a continuum, as opposed to a dichotomous MCI diagnosis. The cognitive 
composites included in this analysis are outlined in Section 2.3., and are the same 
measures that determined MSLS MCI diagnosis (See Section 2.6.). 
Hypothesis: We expect the CVRFS to prospectively predict each of the cognitive 
composite scores (Verbal Memory, Visuospatial Organization and Memory, 
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Scanning and Tracking, Working Memory, Executive Function, and Global 
Function) in linear regression models including age, sex, education, and 
ethnicity.  
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2. METHODS 
 
2.1. The Maine Syracuse Longitudinal Study Design 
 
 The Maine Syracuse Longitudinal Study (MSLS) was started in 1974, and has 
assessed the relationship of cardiovascular health to cognitive functioning over several 
decades. Initially, the study was primarily interested in idiopathic and uncomplicated 
hypertension but has since expanded to include various cardiovascular risk factors 
including arterial stiffness, diabetes, plasma homocysteine, cholesterol levels, kidney 
function, cardiovascular diseases, and nutritional determinants of cognitive 
performance, including vitamins. The MSLS includes seven waves of examination with 
seven cohorts of participants defined by time of entry into the study. A total of 2464 
participants have participated in at least one examination (See Table 3.). The first four 
waves of the study were conducted at SUNY Heath Science Center Upstate New York 
via collaboration between Merrill F. Elias, Principal Investigator, and David H. P. 
Streeten, investigator and Professor of Medicine.  In 1996 the Maine Syracuse 
Longitudinal Study acquired its own laboratory space in Syracuse, New York but 
  W1   W2   W3   W4   W5   W6    W7  
              
C1 E1 → E2 → E3 → E4 → E5 → E6 → E7 
C2   E1 → E2 → E3 → E4 → E5 → E6 
C3     E1 → E2 → E3 → E4 → E5 
C4       E1 → E2 → E3 → E4 
C5         E1 → E2 → E3 
C6           E1 → E2 
C7             E1 
N 234   494   679   717   1506   1176   841 
Table 3. Design of the MSLS 
W= Wave C=Cohort E=Exam  
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continued to collaborate with medical staff at SUNY Health Sciences Center. Figure 4. 
displays the different locations involved in the MSLS study including where specific 
assays were done.  
 
 
The MSLS has a long history of relating cardiovascular risk factors to cognitive 
functioning along a continuum, setting the framework for using similar risk factors to 
predict a dichotomous variable like MCI. A recent review of the literature summarizes 
these studies in the context of the history of the study of cognitive performance and 
hypertension (M.F. Elias et al., 2012). The MSLS was the first longitudinal study 
designed to examine relations between hypertension and cognition over the lifespan, 
following a small initial study by Wilkie and Eisdorfer (Wilkie & Eisdorfer, 1971). Here we 
summarize data from particularly illustrative studies.  
The MSLS has previously shown a negative relationship between high blood 
pressure and cognitive function (Crichton, Elias, Davey, & Alkerwi, 2014; M F Elias, 
Syracuse Lab 
Cognition/Medical 
Centrex Syracuse 
Panel + Vitamin B12 
Maine 
Data/Admin 
Oxford, UK 
Homocysteine 
 
 
 
 
Cambridge, UK 
Vitamin B6 + C-Reactive Protein 
 
 
 
 
 
Birmingham, UK 
ApoE 
Figure 4. MSLS Structure and Assessment Locations 
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Robbins, Elias, & Streeten, 1998; P. K. Elias, Elias, Robbins, & Budge, 2004), as well 
as blood pressure variability across measurements and cognitive function (Crichton, 
Elias, Dore, Torres, & Robbins, 2014). The study has furthermore evidenced 
relationships between lipid profiles and cognitive function (Crichton, Elias, Davey, 
Sullivan, & Robbins, 2014), arterial stiffness as measured by PWV and cognitive 
function (M.F. Elias et al., 2009; M F Elias, Crichton, & Abhayaratna, 2015), as well as 
an interactive effect of the APOE ε4 allele and diabetes on cognitive functioning (G. A. 
Dore et al., 2009). An interaction between APOE genotype and homocysteine has also 
been reported (M F Elias et al., 2008). Many of these studies are prospective in design, 
using risk factors to predict cognitive function after a period of several years. The 
current study uses a similar methodology to these past projects, which support our 
preliminary hypotheses in their findings.  
2.2. Procedure 
 
 Paper and pencil questionnaires including general medical information, 
demographic data, job stress questions, sleep disturbance, Cornell Medical Index, and 
health habits (vitamins, supplements, smoking, alcohol consumption etc.) are completed 
at home. Participants then came into the lab around 9 AM following a fasting period 
from midnight (unless diabetic). Participants in the study provided medical interview 
information on physical health, mental health, and demographics prior to 
neuropsychological testing. Blood samples were taken first when the participant arrived, 
followed by fifteen blood pressure measurements (five each recumbent, sitting, and 
standing) and pulse wave analysis (PWV). Following a light breakfast, a physical 
examination with medical history review and review of current treatments and 
37 
 
medications was done. The participant then participated in the MSLS 
Neuropsychological Battery consisting of over twenty tests and subscales including the 
Wechsler Memory Scale-Revised (WMS-R), the Wechsler Adult Intelligence Scale-III 
(WAIS-III), Mini Mental State Exam (MMSE), and Boston Naming Test among several 
other assessments. Assessment order was identical across all participants. Cognitive 
testing was done at each of the seven waves of the studies with small variations in test 
types due to scale revisions, and measurement of additional cognitive domains. 
Following the examination a summary of each subject’s medical and cognitive 
examination was sent to them with a request that they (the study participants) contact 
their family physician or other specialist and go over the report with them.  
2.3. The MSLS Cognitive Test Battery 
 
 Cognitive performance was first assessed via the original Wechsler Intelligence 
Scale and the Halstead-Reitan Neuropsychological Test Battery. In 1993 the 
Framingham Test Battery was added as a special subset of tests. Eventually specific 
tests were chosen to be given at each wave and defined as the Maine Syracuse 
Longitudinal Test Battery. The test battery used continuously distributed cognitive tests, 
however many clinical tests were available for use in diagnosis of clinical impairment.  
 The “MSLS Battery” (core battery) tests used to derive composite scores (factors 
or domains) and the names of the composite scores are outlined in Appendix C. The 
scores used were all continuously distributed and were largely taken from the Wechsler 
Intelligence Scale and the Wechsler Memory Scales. These composite scores include 
Visual Spatial Memory and Organization, Verbal Memory, Working Memory, Scanning 
and Tracking (See Appendix C for a list of composite scores and tests factored into 
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each composite). WAIS Similarities loaded about equally across factors and thus was 
used as an independent single test of abstract reasoning. Later an executive functioning 
composite was added including Trail Making and Controlled Oral Word Associations. 
These composite scores are represented in Z scores with a mean of 0 and SD of 1, 
reflecting performance relative to the entire community-based sample. The core battery 
also included administration of the MMSE, which is sensitive to cognitive decline over 
repeated assessments. 
2.4. Cardiovascular Risk Factors 
 
2.4.1. Blood Pressure 
 
 Blood pressure (mmHg) was measured in the MSLS using a pressure cuff with a 
Critikon Dinamap ProCare 100. Five measures each were taken in standing, sitting, and 
reclining position, with a five minute interval in between each measurement. For these 
analyses, an average of all 15 measurements was used for systolic blood pressure 
(SBP). The average BP across all 15 measurements was also used as a cut off score 
for hypertension. Pulse Pressure (PP) was calculated by taking the difference in 
average SBP and DBP (see Crichton et al. 2014).  
2.4.2. Arterial Stiffness 
 
 As part of a new grant and a new direction at Wave 7 of the MSLS, arterial 
stiffness was assessed non-invasively using PWV analysis. Using the SphygmoCor 
system (AtCor Medical), PWV was measured in supine position with applanation 
tonometry. Carotid-femoral path length was defined as the difference between the 
surface distances of the suprasternal notch, the umbilicus, and the femoral pulse, as 
well as the suprasternal notch and the carotid pulse. Transit time was estimated in 8 to 
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10 sequential Electrocardiogram-gated femoral and carotid waveforms as the average 
difference between the start of the femoral and carotid waves. PWV was calculated as 
the carotid-femoral path length (meters) divided by the carotid-femoral transit time 
(seconds). 
2.4.3. Homocysteine  
 
 Plasma Hcy levels were measured using a fluorescence polarization 
immunoassay on an Abbot IMx auto-analyzer at the University of Oxford. Blood 
samples were drawn following a period of fasting from midnight. The coefficient of 
variation for the tHcy assays was less than 3.5% (M F Elias et al., 2006). 
2.4.4. Serum Lipids 
 
 Serum lipids including TC, HDL, LDL, and TRIG were obtained from fasting blood 
samples using standard assay methods at Centrex Clinical Laboratories. Lipid levels 
are presented in milligrams per deciliter blood.  Details of blood draws and assays can 
be seen in Elias et al. (2006). 
2.4.5. Diabetes  
 
 Type 2 Diabetes in the MSLS was defined objectively by treatment with insulin or 
glucose lowering medications, or by a fasting glucose greater than 126 mg/dL 
determined by serum analysis by Centrex Clinical Laboratories. 
2.4.6. Renal Function 
 
 Kidney function in the MSLS is measured by GFR using the CKD-EPI formula 
comprising age, sex, ethnicity, and serum creatinine. Fasting blood samples were 
collected in serum separator tubes and sent to Centrex Clinical Laboratories in 
Syracuse, NY for determination of serum creatinine. Serum creatinine was determined 
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using a two-point rare test type on a Johnson and Johnson Vitros Intrument. Coefficient 
of variation was less than 5%. 
2.4.7. APOE 
 
 APOE genotyping was in the laboratory of David A. Smith, Chairman of the 
Department of Pharmacology, University of Oxford, UK, using state of the art methods 
of polymerase chain reaction and restriction enzyme digest with HhaI (Hixson & Vernier, 
1990). Genotyping was done with interest in determining the presence of the E4 allele, 
a risk factor for several brain pathologies and cognitive impairment in late life.  
2.5. Cardiovascular Risk Scores 
 
2.5.1. The MSLS Cardiovascular Risk Factor Scale 
 
The MSLS Cardiovascular Risk Factor Scale (MSLS-CVRFS) is a count of 
dichotomized cardiovascular conditions and biometrics intended to represent a 
participant’s cardiovascular health in terms of clinically defined risk factors. Unlike the 
other risk scores presented in this study, the scale is not intended to predict risk for 
future CVD but is rather intended to represent a current assessment of a participant’s 
cardiovascular condition. The current version of the scale represents 12 risk factors that 
either reflect binary disease states (hypertension, diabetes etc.) or have been 
dichotomized based on clinically recommended cutoffs (lipid levels, kidney function 
etc.). The risk factors included in the scale are as follows: hypertension (≥140 SBP 
and/or ≥90 DBP), diabetes, cardiovascular disease (history of 1 or more of angina 
pectoris, coronary artery disease, myocardial infarction, heart failure, and transient 
ischemic attack), Obesity (≥30 BMI), Apoe ε4 (presence of 1 or 2 ε4 alleles), smoking 
(current smoker), Low HDL (<40 mg/dL), High LDL (>160 mg/dL), High TRIG (>200 
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mg/dL), High THCY (>13 μmol/L), High CRP (>3 mg/L), Low EPI GFR (<60 mL/min). 
These risk factors were then aggregated to form the CVRFS, which ranges in score 
from 0 (no risk factors) to 12 (all 12 risk factors included in the scale).  
 Five hundred and ninety participants in the sample had complete data for all 12 
cardiovascular risk factors (35 participants were excluded for missing data) and a 
CVRFS score was calculated for each. Figure 5. displays the frequency of each score 
on the cardiovascular scale (e.g. 56 individuals in the sample had no cardiovascular risk 
factors). The mean CVRFS score was 2.67 (SD=1.75) with a median and mode of 3.  
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The CVRFS is slightly skewed due to a small number of individuals (n=5) having 
scores beyond CVRFS=7 (see Figure 5.). To adjust the scale and meet assumptions for 
normality required for a linear regression, the scale was truncated to include these five 
individuals in a new CVRFS=7+ category (see Figure 6.). This new distribution is 
relatively normal and was used to conduct the linear regressions. With truncation the 
CVRFS had a mean of 2.65 (SD=1.70), a median of 3, and a mode of 3. Although 
normality is not a requirement for logistic regression the truncated version of the CVRFS 
was used in all analyses for consistency.  
 
 
 
 
 
 
 
 
 
 Table 4. displays the frequency of each risk factor at various levels of the 
CVRFS. Hypertension was the most common risk factor at each level of the scale, 
representing 32% of the participants who had just one risk factor, and was present in 
95% of the participants who scored ≥ 5 on the CVRFS. Proportion of each risk factor 
increased with increasing CVRFS score, and while certain risk factors were more 
common (hypertension, obesity etc.) we feel each risk factor included in the scale is 
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adequately represented. Basic demographic info is also displayed. On average, the 
groups that scored higher on the CVRFS appeared to be slightly older, less educated,  
and had a higher proportion of males and non-white individuals. 
2.5.2. The Framingham Risk Score 
 
 The FRS is described in detail in Section 1.6.1. The score was calculated at 
baseline for MSLS participants consistent with the scoring tables presented in 
D’Agostino et al 2008 and Appendix A. The FRS is based off an individual’s sex, age, 
HDL, TC, SBP, hypertensive treatment, smoker status, and diabetic status. A higher 
FRS score indicates a higher CVD risk over 12 years follow-up. The FRS was only 
Table 4. Proportion of Sample with each Risk Factor in the CVRFS by Number of Risk Factors + 
Demographics 
Risk Factor 
CVRF=0 
N= 56 
CVRF=1 
N=106 
CVRF=2 
N=129 
CVRF=3 
N=130 
CVRF=4 
N= 86 
CVRF=5+ 
N=83 
Hypertension 0 .32 .56 .74 .81 .95 
Diabetes 0 .01 .03 .09 .16 .43 
Cardiovascular 
Disease 
0 0.00 .05 .15 .17 .39 
Obesity 0 .05 .33 .58 .63 .76 
Apoe ε4 0 .24 .25 .30 .41 .41 
Current Smoker 0 .03 .07 .08 .12 .22 
Low HDL 0 .01 .05 .12 .22 .48 
High TRIG 0 .02 .04 .10 .24 .51 
High LDL 0 .10 .12 .15 .21 .14 
High THCY 0 .02 .05 .09 .13 .33 
High CRP 0 .17 .35 .50 .67 .72 
Low GFR 0 .04 .10 .10 .22 .41 
Demographics             
Age (years) 
58.93 
(11.3) 
61.34 
(13.15) 
63.07 
(13.09) 
61.48 
(10.65) 
64.78 
(10.72) 
62.71 
(11.12) 
Sex (% female) 71% 66% 60% 62% 58% 49% 
Education (years) 
15.8 
(2.34) 
14.95 
(2.82) 
14.50 
(2.883) 
14.93 
(2.57) 
14.41 
(2.42) 
13.33 
(2.61) 
Ethnicity (% 
white) 100% 94% 96% 95% 93% 80% 
Standard deviation presented in parentheses where applicable 
44 
 
utilized in this study for participants with complete data for the variables included in the 
algorithm (n=615). The sample had a mean FRS of 12.87 (SD=5.54) with risk scores 
ranging from -3 to 25. The FRS can also be converted to a risk percentage for CVD 
using conversion tables presented in D’Agostino et al 2008, though this approach was 
not used for this study. 
2.5.3. The Arteriosclerotic Cardiovascular Disease Risk Score 
 
 The ASCVD Score is described in detail in section 1.6.1. The score is 
represented as a 10-year risk percentage for arteriosclerotic CVD. The ASCVD risk 
score was calculated for MSLS participants consistent with the risk algorithms 
presented in (Goff et al., 2014) and Appendix B. Like the FRS, the ASCVD includes sex, 
age, HDL, TC, SBP, hypertensive treatment, smoker status, and diabetic status. The 
scoring algorithm also incorporates ethnicity, with separate coefficients for whites and 
African Americans. ASCVD risk score was only calculated for white or African American 
participants who had complete data for the variables included in the algorithm (n=607). 
The sample had a mean ASCVD risk percentage of 15.29% (SD=16.32%) and scores 
ranged from 0% to 85%. 
2.6. Defining MCI in the MSLS 
 
The proposed study uses data from the final two waves of the MSLS (wave 6 and 
7) for two reasons: 1). These waves offer the most complete and comprehensive set of 
data in terms of cardiovascular and cognitive variables; and 2). these waves have the 
highest average age in the study (Wave 6 M=62.43, SD=12.85; Wave 7 M=65.28, 
SD=12.72).This age range targets the potential at-risk population for MCI. Given the 
importance of previous functioning to the diagnosis of MCI, it is necessary to assess 
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decline in function over time (from Wave 6 to 7). 762 study participants were assessed 
at both examinations. Of these participants, 625 had complete cognitive battery data for 
both waves. These examinations were an average of 5 years apart (M=4.64, SD=.72), 
allowing a decline in function from a previous baseline. Therefore, MCI diagnosis is 
made at Wave 7 if the criterion for decline is met.  
 The MSLS has not included a formal diagnosis of possible MCI prior to the 
proposed work, albeit dementia has been defined. The MSLS categorization for 
possible MCI is based on common MCI criteria outlined in Section 1.4.2. The individual 
must be free from dementia, have maintained independence in daily function, and show 
a decline in cognitive function from previous level. Thus for both waves 6 and 7, 
exclusions from the sample were for dementia (as defined by the MSLS dementia 
committee and current criteria). Subjects with diagnosed alcoholism and psychotic 
mental illness or institutionalization, or who could not speak English were excluded from 
the study the study at its inception. There was no restriction on age at entry into the 
study. However, it has always been the policy that individual investigators may use their 
own set of exclusions as dictated by study goals. Such is the case for the proposed 
work.  
The criteria used for diagnosis of MCI are sensitive to single-domain or multi-
domain MCI in that the individual would be marked as possible MCI with a large 
decrease in performance in one domain, or with smaller decreases in performance 
across multiple domains. Initially, we used the commonly employed criterion of a drop in 
performance of 1 SD, and considered this a sign of possible MCI. A drop of .5 SD in 
multiple domains (or Global Function) was considered possible MCI to include multi-
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domain phenotypes in order to identify persons who show a drop in performance in 
multiple cognitive domains.  These domains are outlined in Appendix C. However, 
because archival diagnosis of MCI can be difficult, we decided to increase the 
requirements for possible diagnosis to a 1.5 SD drop in a single domain or multiple 1 
SD drops across several domains (or Global Function). These stricter criteria were used 
in an effort to limit false positive diagnoses. Additionally, a drop in MMSE score of 4 or 
more was considered an additional marker of possible MCI, as this is a large drop over 
5 years. This criterion alone does not suffice as an indicator of MCI because persons 
can drop 3 points or more and return to normal functioning on the MMSE at a third 
measurement point. Figures 7-9. display the pattern of cognitive changes from baseline 
to follow-up between participants categorized as MCI vs CN (Non-MCI).  
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48 
 
2.7. Sample Characteristics  
 
 Following exclusions for probable dementia (n=6), a total sample of 625 
individuals was examined at both Waves 6 and 7 of the MSLS and had complete 
cognitive battery data to inform MCI diagnosis. 96 (15.4%) participants met the criteria 
for probable MCI outlined in Section 2.6. This proportion is consistent with other large 
community based studies and MCI prevalence meta-analyses (Ganguli et al., 2010; R. 
Petersen et al., 2010). Subsequently, 529 participants were considered free from 
dementia or MCI and were categorized as Non-MCI or CN. Average baseline age for 
the non-MCI sample was 60.70 (SD=11.50), whereas average age for the MCI sample 
was 69.01 (SD=11.51). Activities of daily living were not compromised in either sample, 
consistent with common MCI diagnostic criteria. The sample was largely community 
dwelling individuals who should be representative of the normal population for these 
age ranges. A preliminary look at the demographic data suggests some difference in 
cardiovascular risk factors between the two groups, with the MCI sample showing 
slightly higher BP, PWV, THCY, and higher incidence of diabetes and stroke (See Table 
5. on the following page).  
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Table 5. Demographics Table  
  Baseline (Wave 6) Follow-up (Wave 7) 
Variable 
Non-MCI 
(n=529) 
MCI 
(n=96) 
Non-MCI 
(n=529) 
MCI 
(n=96) 
Age (years) 60.70 (11.50) 69.01 (11.51) 65.39 (11.46) 73.61 (11.55) 
Sex (% Female) 63% 49% 63% 49% 
Education (years) 14.63 (2.70) 14.49 (2.87) 14.70 (2.72) 14.36 (2.86) 
Ethnicity (% white) 92% 96% 92% 96% 
MMSE (Total Score) 28.33 (1.87) 28.34 (1.91) 28.09 (1.95) 25.80 (2.86) 
Global Composite (Z-Score) .19 (.90) -.33 (.93) .20 (.92) -.86 (1.00) 
Diabetes (% Diabetic) 10% 18% 15% 22% 
CVD (% Have/had CVD) 11% 20% 16% 31% 
BMI  29.63 (6.19) 28.90 (4.69) 29.98 (6.88) 28.28 (4.84) 
SBP (mmHg) 129.52 (21.47) 134.91 (23.07) 129.89 (19.91) 136.00 (23.16) 
PWV (m/s) n/a n/a 10.47 (2.95) 11.78 (3.61) 
THCY (μmol/L ) 9.56 (3.23) 10.42 (3.09) 10.40 (3.69) 11.74 (3.97) 
TC (mg/dL) 203.75 (40.12) 196.25 (39.69) 188.56 (39.42) 174.15 (40.51) 
HDL (mg/dL) 54.79 (15.87) 51.01 (13.84) 53.02 (49.25) 49.25 (13.82) 
LDL (mg/dL) 121.98 (33.65) 116.54 (34.36) 112.59 (32.41) 101.04 (34.96) 
TRIG (mg/dL) 139.47 (109.04) 147.47 (100.59) 116.64 (77.96) 118.82 (59.91) 
GFR (mL/min 79.02 (16.24) 69.46 (17.96) 66.31 (15.74) 58.21 (16.23) 
APOE (% have at least 1 ε4) 28% 30% 28% 30% 
Smoking (% current smoker) 11% 3% n/a n/a 
Hypertensive Meds (% 
Treated) 
47% 57% 57% 70% 
CVRFS 2.57 (1.69) 3.09 (1.68) n/a n/a 
FRS 12.44 (5.57) 15.24 (4.75) n/a n/a 
ASCVD Risk Score (%) 13.35% (14.35%) 25.75% (21.59%) n/a n/a 
 
2.8. Statistical Analysis Strategy 
 
2.8.1. Logistic Regression 
 
Given the nature of our continuous predictor variables (cardiovascular risk factors 
such as BP, PWV, and tHcy) and a dichotomous outcome variable (MCI; yes/no), we 
will be employing a logistic regression model (Hosmer & Lemeshow, 1989). Unlike 
traditional linear regression, which has been  often been used  in previous MSLS 
studies to assess the relationship between continuous predictor variables and cognitive 
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performance along a similar continuous scale, logistic regression provides probabilities 
of a binary outcome dependent on the predictor variables included in the model. These 
odds ratios fit the medical model of binary diagnosis and can be used to predict MCI risk 
based on the levels of several cardiovascular variables and covariates. Assumptions 
are largely in common with linear regression with regards to absence of multicollinearity 
or outliers with undue leverage on the regression equation. However, logistic regression 
does not require normally distributed predictor variables (Hosmer & Lemeshow, 1989). 
Because change in probability is not linear, the logistic regression maps observed data 
onto a logistic function containing the natural logs of each possible odds ratio. This logit 
scale is continuous, therefore the log of the odds ratios form a linear function of the 
predictor variables. This procedure is useful for assessing relative risk given a model of 
cardiovascular variables and covariates, and will indicate whether an aggregation of one 
or more risk factors increases the likelihood and individual will be in the MCI group. One 
important assumption in logistic regression analysis is that associations between risk 
and outcome variables are linear, albeit in the absence of linearity one employs other 
scaling methods, e.g. examine quartiles of performance rather than scaling predictors 
as continuously distributed. In this study logistic regression will be used to assess the 
association of various cardiovascular risk factors and MCI risk. It will not be used as a 
classification procedure.  
2.8.2. Covariates 
 
 Like traditional linear regression, logistic regression also allows for the inclusion 
of covariates in the model in a way similar to linear regression analysis except that the 
outcome is a yes/no dichotomy.  Our selection of covariates is based first on theory and 
51 
 
clinical relevance, and secondly on empirical examination of relations between 
predictors and outcomes. In classical epidemiology there is a requirement that a 
variable not be considered a confounder unless it relates to the predictor and outcome. 
However, consistent with the behavioral and social sciences we consider theory and 
clinical relevance as of the first importance in adding variables. 
 A significant problem in modeling is that too many covariates will reduce total 
variance to the point where there are no results. Consequently, we model in hierarchical 
fashion, beginning with zero-order relations, adding a basic demographic mode (age, 
sex, education, and ethnicity) and subsequent models until model R2 values indicate no 
better prediction of outcomes with added models.  We also use backward elimination 
procedures, but always lock theoretically relevant variables in the models. Covariate 
models in this study will focus on basic demographic info including age, sex, education, 
and ethnicity.  
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3. RESULTS 
 
3.1. Cardiovascular Risk Factors Predicting MCI 
 
We prospectively predicted MCI with several cardiovascular risk factors and 
hypothesized that higher levels of these factors would predict an increased risk of MCI 
(with the exception of HDL and GFR, which we expected to be associated with lower 
risk). Table 6. displays the results of a series of logistic regression analyses testing 
these hypotheses with a zero-order model and a basic covariate model adjusting for 
age, sex, education, and ethnicity. The assumptions of logistic regression, including 
Hosmer and Lemeshow tests of model fit, were all met unless otherwise mentioned. 
 Systolic Blood Pressure (SBP; b=.011, p=.026, OR=1.011) and Plasma 
Homocysteine (THCY; b=.069, p=.022, OR=1.071) were both positively associated with 
MCI as predicted. However neither of these associations remained with adjustment for 
the basic model covariates (SBP: b=-.002, p=.748, OR=.998; THCY: b=.018, p=.59, 
OR=1.019). 
 High density lipoprotein (HDL; b=.-.017, p=.03, OR=.983) and Estimated 
Glomerular Filtration Rate (GFR; b=-.024, p<.001, OR=.976) were both negatively 
associated with MCI consistent with our initial hypotheses. These associations 
remained with adjustment for basic model covariates (HDL: b=-.02, p=.022, OR=.980; 
GFR: b=-.017, p=.015, OR=.983). 
In a cross sectional analysis PWV was significantly associated with MCI (b=.122, 
p=.001, OR=1.130). However this association did not remain under adjustment for the 
basic model (b=.012, p=.806, OR=1.012). 
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Table 6. Logistic Regression Results: Cardiovascular Risk Factors Predicting MCI with Adjustment for Basic 
Model Covariates 
  Zero-Order Basic Model Adjustment 
  b χ²(df) p OR 
95% CI 
(OR) 
b χ²(df) p OR 
95% CI 
(OR) 
SBP 0.011 4.927 (1) 0.026* 1.011 1.001:1.021 -0.002 .103 (1) 0.748 0.998 .987:1.01 
TC -0.005 2.828 (1) 0.093 0.995 .990:1.001 -0.003 1.076 (1) 0.3 0.997 .991:1.003 
HDL -0.017 4.689 (1) 0.03* 0.983 .968:.998 -0.02 5.278 (1) 0.022* 0.98 .963:.997 
LDL -0.005 2.053 (1) 0.152 0.995 .988:1.002 -0.003 .848 (1) 0.357 0.997 .989:1.004 
TRIG 0.001 0.444 (1) 0.505 1.001 .999:1.002 0.001 2.077 (1) 0.15 1.001 .999:1.003 
GFR -0.024 12.513 (1) <.001* 0.976 .964:.989 -0.017 5.875 (1) 0.015* 0.983 .969:.997 
THCY 0.069 5.277 (1) 0.022* 1.071 1.010:1.136 0.018 .290 (1) 0.59 1.019 .952:1.089 
DIABETES 0.618 4.157 (1) 0.041* 1.855 1.024:3.358 0.62 3.622 (1) 0.057 1.859 .982:3.520 
PWV^ 0.122 10.348 (1) 0.001* 1.13 1.049:1.217 0.012 .06 (1) 0.806 1.012 .923:1.109 
 
 
3.2. APOE Interaction Terms Predicting MCI 
 
Theoretically relevant cardiovascular risk factors included in the above analyses 
and the CVRFS were used to create interaction terms with APOE genotype (ε4 carrier 
or not). Out of 614 subjects in the present study with APOE data, 442 have no ε4 alleles 
while 172 are ε4 carriers. There was no main effect of APOE in any of the analyses 
performed, and in a separate analysis APOE was not significantly associated with MCI 
in a simple single factor ANOVA [F(1,612)=.271, p=.603, η2=.000], with 15.2% of non-
ε4 carriers having MCI compared to 16.9% of ε4 carriers having MCI.  
Table 7. displays the results of these APOE interaction analyses as part of a 
logistic regression analysis with a model including both variables in the interaction term, 
as well as basic model covariates. Of the variables tested, only LDL demonstrated 
significant interactions with APOE, however Hosmer and Lemeshow model fit statistics 
suggested the LDL X APOE interaction model did not fit the observed data and should 
not be interpreted as a significant effect. 
* p<.05  ^ cross-sectional analysis 
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Table 7. Logistic Regression Results: APOE Interaction Terms Predicting MCI with Adjustment for Basic Model 
Covariates 
  Zero-Order Basic Model Adjustment 
   
  b χ²(df) p OR 
95% CI 
(OR) 
b χ²(df) p OR 
95% CI 
(OR) 
APOE*SBP 0.006 .348 (1) 0.555 1.006 .986:1.028 -0.001 0.005 (1) 0.943 0.999 .976:1.022 
APOE*TC 0.003 .308 (1) 0.579 1.003 .991:1.016 0.003 .165 (1) 0.685 1.003 .990:1.016 
APOE*HDL -0.014 0.634 (1) 0.426 0.986 .953:1.020 -0.01 0.319 (1) 0.572 0.99 .957:1.025 
APOE*LDL 0.015 3.966 (1) 0.046* 1.015 1.00:1.031 0.014 3.188 (1) 0.074 1.014 .999:1.030 
APOE*TRIG -0.004 2.962 (1) 0.085 0.996 .991:1.001 -0.005 3.553 (1) 0.059 0.995 .989:1.000 
APOE*GFR 0.017 1.510 (1) 0.219 1.017 .99:1.046 0.021 2.032 (1) 0.154 1.021 .992:1.051 
APOE*THCY -0.003 .002 (1) 0.962 0.997 .867:1.145 -0.017 0.041 (1) 0.839 0.983 .837:1.155 
APOE*DIABETES 0.104 .026 (1) 0.871 1.11 .314:3.923 0.39 .327 (1) 0.567 1.477 .388:5.621 
 
 
3.3. MSLS-CVRFS and MCI 
 
3.3.1. Analysis 
 
A logistic regression analysis was done to predict possible MCI at 5 year follow 
up from number of risk factors on the MSLS-CVRFS. Five-hundred and ninety subjects 
were included in the analysis, with 94 (15.9%) having possible MCI. The sample had a 
mean CVRFS score of 2.65 (SD=1.70) and a range of 0-7. Refer to Section 2.5.1. in the 
methods for the full distribution of scores.  
3.3.2. Model Fit 
 
A Hosmer and Lemeshow test for model fit determined that the MCI values 
predicted by the model did not significantly differ from observed values (χ²=7.441, df=8, 
p=.49). Therefore the predicted rates by the model reliably matched the observed rates 
of MCI in the sample, and further interpretation of regression analysis was possible. 
Figure 10. displays zero-order model predicted MCI relative to observed MCI rates in 
the sample. 
* p<.05 
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3.3.3. Relation of MSLS-CVRFS to MCI 
 
The MSLS-CVRFS score at Wave 6 predicted follow up MCI at Wave 7 with 
adjustment for the basic model covariates (b=.170, χ²(1)=5.469, p=.019, OR=1.186, 
95% CI OR: 1.028-1.368). The MSLS-CVRFS also predicted MCI in a zero-order model 
(b=.173, χ²(1)=7.147, p=.008, OR=1.189, 95% CI OR: 1.047-1.349). The odds ratio for 
the full model can be interpreted such that for every 1 unit increase in risk (CVRFS 
score) the odds associated with MCI increased by 18.6%. However, examination of the 
data determined that there are not equal units of risk with increases in the MSLS-
CVRFS, and therefore a different analysis and interpretation was necessary. As is 
commonly done we compared different levels of the MSLS-CVRFS to a CVRFS=0 
referent group representing zero risk. Table 8. displays odds ratios evidencing 
increased MCI risk for subjects with an increasing risk factor score as compared to a 
zero risk factor referent group. However, the apparent reduction in risk moving from 
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CVRFS=2 to CVRFS=3 warranted further exploration to observe the pattern of 
increased risk with increased CVRFS score. Table 9. displays the same analysis with 
different groupings, with CVRFS=2 and CVRFS=3 being grouped together and CVRFS= 
4+ replacing CVRFS=5+. This reconfiguration of risk factor groups reveals that moving 
from 1 to 2 or 3 risk factors increased the risk of MCI, but the largest increase in risk 
was observed in individuals who exceeded 4 on the CVRFS. These comparisons to a 
CVRFS=0 referent group were made with and without control for the basic covariate 
model. An additional control for physical activity (metabolic equivalents per week) was 
made in a separate analysis but the relation between CVRFS and MCI remained 
significant (p<.05 comparing groups CVRFS=2 or 3 and CVRFS=4+ to referent group). 
Table 8. Odds Ratios (Zero-order and Basic Model Adjusted) for Each Level of CVRFS Compared to 
CVRFS = 0 Referent Group 
    Zero-Order Basic Model Covariates 
CVRFS N Odds Ratio 95 % CI p Odds Ratio 95 % CI p 
0 (referent) 56 n/a n/a n/a n/a n/a n/a 
1 106 4.109 0.899 – 18.772 0.068 3.268 .681 - 15.687 0.139 
2 129 6.49 1.481 – 28.4363 0.013* 5.227 1.152 - 23.724 0.032* 
3 130 4.062 0.906 – 18.216 0.067 3.363 .733 - 15.440 0.119 
4 86 6.652 1.4727 – 30.048 0.014* 4.586 .958 - 21.945 0.057 
5+ 83 7.172 1.586 – 32.442 0.011* 5.638 1.152 - 27.605 0.033* 
 
 
Table 9. Odds Ratios (Zero-order and Basic Model Adjusted) for Each Level of CVRFS Compared to 
CVRFS = 0 Referent Group (New Grouping) 
    Zero-Order Basic Model Covariates 
CVRFS N Odds Ratio 95 % CI p Odds Ratio 95 % CI p 
0 (referent) 56 n/a n/a n/a n/a n/a n/a 
1 106 4.109 0.899 – 18.772 0.068 3.268 .681 - 15.687 0.139 
2,3 259 5.226 1.226 – 22.268 0.025* 4.384 1.007 - 19.083 0.049* 
4+ 169 7.308 1.700 – 31.425 0.008* 5.067 1.128 - 22.767 0.034* 
 
 
* p<.05 
  
* p<.05 
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3.4. FRS and MCI 
 
3.4.1. Analysis 
 
A logistic regression analysis was done to predict possible MCI at 5 year follow 
up from the FRS. Six hundred and fifteen participants were included in the analysis, with 
96 (15.6%) having possible MCI. The sample had a mean FRS of 12.87 (SD=5.54) and 
ranged from -3 to 25. Figure 11. displays the frequency of FRS in the sample. Because 
the FRS algorithm includes age and sex, the basic model covariates included in the 
model for this analysis were limited to years of education and ethnicity.  
 
 
3.4.2. Model Fit 
 
 A Hosmer and Lemeshow test for model fit determined that the MCI values 
predicted by the model did not significantly differ from observed values (χ²=7.413, df=8, 
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p=.49). Therefore the predicted rates by the model reliably matched the observed rates 
of MCI in the sample, and further interpretation of regression analysis was possible.  
3.4.3. Relation of FRS to MCI 
 
FRS at Wave 6 predicted 5 year follow up MCI (b=.101, χ²(1)=19.599, p<.001, 
OR=1.106, 95% CI OR: 1.058-1.157). The odds ratio can be interpreted such that for 
every 1 point increase in FRS the odds associated with MCI increased by 10.6%. 
3.5. ASCVD Risk Score and MCI 
 
3.5.1. Sample 
 
A logistic regression analysis was done to predict possible MCI at 5 year follow 
up from ASCVD risk score. Six hundred and seven participants were included in the 
analysis, with 95 (15.7%) having possible MCI. The sample had a mean ASCVD risk 
score of 15.29% (SD=16.32%) and a range of 0-85. Recall that ASCVD risk score is 
represented as an estimated % of an arteriosclerotic event and therefore can only 
possibly range from 0 to 100. The distribution of ASCVD risk score was skewed, but a 
normal distribution is not a required assumption of logistic regression. Figure 12. 
displays the frequency of ASCVD risk in the sample. Because the ASCVD algorithm 
includes the majority of the basic model covariates utilized in this study, including age, 
sex, and ethnicity, only years of education was added to the model as a covariate.  
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3.5.2. Model Fit 
 
A Hosmer and Lemeshow test for model fit determined that the MCI values 
predicted by the model did not significantly differ from observed values (χ²=3.701, df=8, 
p=.88). Therefore the predicted rates by the model reliably matched the observed rates 
of MCI in the sample, and further interpretation of regression analysis was possible.  
3.5.3. Relation of ASCVD Risk to MCI 
 
 ASCVD Risk score at Wave 6 predicted 5-year follow up MCI (b=.039, 
χ²(1)=39.103, p<.001, OR=1.039, 95% CI OR: 1.027-1.052). The odds ratio can be 
interpreted such that for every 1% increase in ASCVD risk the odds associated with 
MCI increased by 3.9%.  
3.6. Comparison of CV Risk Scores in Predicting MCI 
 
3.6.1 Strategy 
 
 The sample was limited to only participants who had complete data for the 
CVRFS, the FRS, and the ASCVD risk score (N=581). It is important to note that each 
scale represents a different unit of measurement. The MSLS-CVRFS represents entire 
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risk factors and had a mean of 2.65 (SD=1.70). The FRS is represented in an 
algorithmically derived score and had a mean of 12.87 (SD=5.51). The ASCVD risk 
score is represented as an algorithmically derived percentage and had a mean of 
15.35% (SD=16.49%). While it is possible to represent FRS as a risk percentage like 
the ASCVD risk score the scoring algorithm is capped at 30% risk which is a level of 
truncation we decided against in order to maintain variance in the distribution of scores. 
The ASCVD risk score has not been adapted to a simple point scoring system like the 
FRS and therefore it was necessary to use the percentages produced by the algorithm. 
While this disparity in units of measurement complicates any interpretation of a 
comparison between the three scores in predicting MCI, we still feel it is of value to see 
how each score performs at predicting MCI in identical samples. Because of the varying 
degrees to which these scales include the demographic variables employed in this 
study’s basic covariate model (age, sex, education, ethnicity), these comparisons will be 
done as a zero-order logistic regression analysis.  
3.6.2. Correlations 
 
 The CVRFS, FRS, and ASCVD risk score were all highly positively correlated 
with each other as can be seen in Table 10. FRS and ASCVD risk score shared the 
strongest correlation at r=.751 (p<.001), while the CVRFS and ASCVD risk shared a 
comparatively weaker but still significant positive correlation of r=.271 (p<.001).  
 
 
 
 
Table 10. CV Risk Scores Correlations (n=581) 
  CVRFS FRS ASCVD 
CVRFS 1 .501* .271* 
FRS .501* 1 .751* 
ASCVD .271* .751* 1 
* p<.05 
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3.6.3. CV Risk Scores Predicting MCI 
 
 All three scores were used in independent zero-order logistic regression 
analyses to predict 5-year follow up MCI. Hosmer and Lemeshow tests for model fit 
indicated no significant differences between model-predicted MCI and observed MCI 
rates for any of the three models, allowing for further interpretation of the regression 
coefficients. Table 11. displays the regression coefficients and odds ratios for each of 
the three risk scores. The best statistic for comparison of the three models given the 
difference in units are the adjusted R2 values, although interpretation of R2 in a logistic 
regression should be done with caution (Hosmer & Lemeshow, 1989). Despite this 
caution, it is clear that while all three risk scores were significant predictors of MCI at 
follow-up, the ASCVD outperformed the CVRFS and the FRS in terms of percent 
variance in MCI explained.  
 
 
 
 
3.7. Cardiovascular Risk Factor Scale and Cognitive Composite Scores 
 
3.7.1. Sample 
 
A series of linear regression analyses was done to predict continuously 
distributed cognitive composite scores at 5 year follow up from number of risk factors on 
the CVRFS. These analyses employed the same five-hundred and ninety subjects 
included in the logistic regression analysis in Section 3.3. Appendix C displays the 
Table 11. Comparison of CV Risk Scores Predicting MCI (n=581) 
Risk Score b χ²(1) p OR 95% CI (OR) Nagelkerke R2 
CVRFS 0.165 6.502 0.011* 1.18 1.039 : 1.339 0.019 
FRS 0.104 20.412 <.001* 1.11 1.061 : 1.161 0.065 
ASCVD  0.039 40.018 <.001* 1.039 1.027 : 1.052 0.115 
* p<.05 
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cognitive composites and the factor analyzed cognitive tasks that are included in each 
composite score (z-score standardized).  
3.7.2. Relation of CVRFS to Cognitive Composite Scores 
 
Table 12. displays the results of the series of linear regressions predicting the 
cognitive composite scores from CVRFS score with and without adjustment for the 
basic model covariates of age, sex, education, and ethnicity. CVRFS score was 
negatively associated with every composite score in a zero-order regression analysis 
(p<.001) with a model R2 ranging from 3.5% to 8.6%. The CVRFS was negatively 
associated with every composite score in a basic model regression analysis (p<.01) with 
the exception of Verbal Memory (p=.089). Model R2 for the basic model regressions 
ranged from 25.1% to 51.7%. Figure 13. displays CVRFS plotted against 5-year global 
composite follow-up score. A quadratic and cubic trend line fit was tested in addition to 
a linear model, and in some cases a cubic trend resulted in an increase in explained 
variance of 1-1.5%. Appendix D contains additional plotted trends for the CVRFS and 
each of the cognitive composites. 
 
 
Table 12. Linear Regression Analysis Predicting Wave 7 Cognitive Composite Scores from CVRFS 
Score 
  Zero - Order Basic Model Adjustment 
Outcome  b p 95%CI (b) 
Model 
R2 
b p 95%CI (b) 
Model 
R2 
Verbal Memory -0.112 <.001* -.160, -.065 0.035 -0.037 0.089 -.079, .006 0.317 
Visual Organization 
and Memory 
-0.133 <.001* -.179, -.087 0.052 -0.051 .008* -.089, -.014 0.428 
Scanning and 
Tracking 
-0.152 <.001* -.199, -.105 0.064 -0.06 .001* -.096, -.024 0.504 
Working Memory -0.172 <.001* -.218, -.127 0.086 -0.106 <.001* -.149, -.063 0.251 
Executive Functioning -0.149 <.001* -.196, -.101 0.061 -0.068 .001* -.109, -.027 0.354 
Global -0.171 <.001* -.217, -.125 0.082 -0.076 <.001* -.111, -.041 0.517 
* p<.05 
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4. DISCUSSION 
 
The purpose of this study was to provide new information for the role of 
cardiovascular risk factors in the prediction of MCI. Of particular interest was examining 
cardiovascular risk factors that are not well represented in MCI studies. In the first 
phase of the study, individual risk factors were related to MCI. In the second phase of 
the study, a cardiovascular risk scale was constructed and used as a predictor of 
incidence (new cases after baseline) of MCI. The scale was based on a combination of 
risk factors representing general cardiovascular health (MSLS-CVRFS; see section 
2.5.1.). The MSLS-CVRFS was compared to other cardiovascular risk scores used to 
predict cardiovascular-related mortality and disease incidence. 
It has long been known that cardiovascular risk factors and diseases can have a 
negative impact on brain function and structure and thus influence cognitive function at 
all ages (Lertiz, McGlinchey, Kellison, Rudolph, & Milberg, 2012; Waldstein & Elias, 
2015). There have been many studies examining risk factors and cognitive function 
(See Section 1.2.). However there are much fewer studies associating cardiovascular 
health with MCI specifically, especially using cardiovascular risk scores or an aggregate 
score like the MSLS-CVRFS used in the present study. Because MCI is becoming an 
epidemiologically and clinically significant disease state in the progression of dementia, 
it is critically important for studies to identify modifiable risk factors for this condition. 
Several analyses were conducted in this study in an effort to use the MSLS to address 
some of the gaps in the MCI literature with regard to specific risk factors like GFR and 
THCY, as well as cardiovascular risk scores.  
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4.1. Overview of Findings 
 
4.1.1. Cardiovascular Risk Factors  
 
Nine cardiovascular risk factors (SBP, TC, HDL, LDL, TRIG, GFR, THCY, 
Diabetes, and PWV) were used to predict MCI over a 5-year follow up period of the 
present study. Several of these risk factors have not been extensively studied in their 
relation to MCI prospectively including GFR, THCY, and PWV. Several others were 
included in the study in an effort to add support to previous findings relating 
cardiovascular risk factors and MCI: TC, HDL, SBP and diabetes. All of these risk 
factors were assessed not only for their individual contribution to MCI risk, but for any 
possible interactions with APOE genotype given the importance of genetic influences on 
cognitive function. This section discusses results for each risk factor separately in the 
context of the study hypotheses and related studies from the literature.  
In agreement with original hypotheses, GFR was identified as a positive risk 
factor for MCI. Higher GFR, reflecting healthier kidney function, was protective against 
MCI. This finding complements the inverse relationship commonly observed between 
GFR and continuous cognitive functioning (Elias et al., 2009; Kurella, Chertow, Luan, & 
Yaffe, 2004; Kurella, Yaffe, Shlipak, Wenger, & Chertow, 2005; Slinin et al., 2008) but 
the results of the present study provide evidence that GFR can predict MCI, a discrete 
and important clinical outcome. Although kidney function has been associated with risk 
for dementia (Seliger, 2004), and there is some recent cross-sectional evidence that 
GFR and MCI are related (Zammit, Katz, Zimmerman, Bitzer, & Lipton, 2015), very few 
studies have associated kidney function and GFR with MCI prospectively. Mechanisms 
underlying these relations were not examined in the present study, but there is some 
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evidence suggesting kidney function can affect arterial compliance (elasticity and 
responsivity), and this loss of hemodynamic efficiency can be very damaging to the 
small vessels in the brain (See Section 4.3.). 
Elevated THCY was identified as a potential risk factor for MCI, although a 
statistically significant association was not seen with control for basic demographic 
variables, most notably age. This negative association is of interest because THCY has 
been associated with dementia and cognitive impairment no dementia (CIND; a 
conceptualization of MCI) and this association was moderated by vitamin B12 treatment 
such that those with higher vitamin B12 levels had lower risk compared to those with 
lower B12 levels (Mary N. Haan et al., 2007). The contribution of THCY to AD risk may 
be particularly strong, with results from the Framingham study finding showing a 
doubled risk of AD (OR=1.8) in patients for every one standard deviation increase in 
THCY (Seshadri et al., 2002). Homocysteine may play a role in brain health by means 
of endothelial dysfunction via oxidative stress, increasing the risk of vascular damage. 
The damaging effects of hyperhomocysteinemia may contribute to increased risk of MCI 
and dementia (including VaD and AD), but to date lowering of THCY with B vitamin 
treatments has shown little efficacy in reversing or slowing cognitive decline associated 
with these diseases. 
Pulse wave velocity studies undertaken in the present research were not funded 
by NIH prior to MSLS wave 7 and thus could not be assessed as a prospective predictor 
of MCI. However, the current study presents some cross-sectional evidence that arterial 
stiffness is related to MCI risk by confining our analyses to Wave 7 where it was 
available as a predictor variable. Subjects diagnosed with MCI exhibited higher PWV, 
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although this result was not statistically significant with adjustment for age. In another 
study with a higher average age than the present study (78.0 compared to 66.7 in our 
study at Wave 7), PWV was shown to be elevated in patients with dementia (AD or 
VaD) and with MCI compared to CN patients (Hanon et al., 2005). It is important that 
arterial stiffness be examined in relation to MCI in larger studies. Arterial stiffening 
occurs naturally with age but can also occur as a result of pathological atherosclerotic 
processes and it may be a primary mechanism involved in the relation of cardiovascular 
health to the brain. Interestingly, PWV has previously been associated with cognitive 
impairment even in healthy populations (Pase et al., 2010; Scuteri et al., 2007; Scuteri, 
Brancati, Gianni, Assisi, & Volpe, 2005). This may reflect the potential for arterial 
stiffness to damage brain areas via a reduction in hemodynamic efficiency (O’Rourke & 
Safar, 2005).  
 We now consider our results for cholesterol. Most notable among the current 
study’s results for serum lipids was HDL cholesterol’s role as a potent positive factor 
protecting against MCI risk. HDL has been reported previously as a protective factor 
with regard to cognitive decline and cardiovascular disease (Crichton, Elias, Davey, 
Sullivan, & Robbins, 2014b; Reitz et al., 2008), but evidence for it as a protective factor 
against MCI risk is has been sparse prior to the present study. No relationship was 
found between TC, LDL, and TRIG with MCI, which supports some previous findings 
(Reitz, 2008). As noted earlier, the importance of this finding for MCI in the present 
study is that it is a clinically defined outcome that allows yes or no treatment decisions, 
an essential requirement in medical diagnosis and disease management (Evans, 1988). 
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SBP was shown to be a risk factor for MCI in the current study in zero order 
analyses, but not with adjustment for age. The history of hypertension and cognitive 
function is well defined, with many studies providing evidence that mid-life hypertension 
and higher BP levels are associated with cognitive decline in late life (M.F. Elias et al., 
2012). Past studies with the MSLS data indicate that blood pressure often has to be 
combined over multiple waves in order to see associations with cognitive performance 
(M.F. Elias, Goodell, & Robbins, 2015; M.F. Elias et al., 2012, 1993). The current study 
takes blood pressure from only one wave of examination like the other cardiovascular 
risk factors included as predictors. Additionally, the present study has a smaller sample 
size and used a discrete MCI outcome in comparison to past blood pressure studies 
from the MSLS that associate hypertension with continuously distributed cognitive 
function (M.F. Elias et al., 1993). There is also now a fair amount of evidence relating 
blood pressure and hypertension to MCI specifically (M Kivipelto et al., 2001; O. L. 
Lopez et al., 2003; Reitz et al., 2007). Reitz et al 2007 specifically found that 
hypertension predicted all-cause MCI and non-amnestic MCI but not amnestic MCI, 
which adds to evidence suggesting amnestic MCI may be more associated with AD 
pathology and non-amnestic MCI may be more associated with vascular pathology. 
However these distinctions are not conclusive; outcomes for various MCI subtypes are 
not so easily predicted (Busse, Hensel, Guhne, Angermeyer, & Riedel-Heller, 2006b) 
and dementia pathologies (particularly AD and VaD) are often mixed (See Section 
1.3.3.) 
Diabetes mellitus was identified as a risk factor for MCI in the present study even 
with adjustment for basic demographics, with higher incidence of MCI seen in subjects 
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who were diabetic at baseline. This finding is consistent with results reported in several 
previous studies as diabetes has previously been reported as a prospective MCI risk 
factor (O. L. Lopez et al., 2003; J. A. Luchsinger et al., 2007) and provides supporting 
evidence to the claim that there may be a higher incidence of MCI among Type 2 
diabetics (Cheng et al., 2012). As is true for hypertension, there is an established 
literature base relating diabetes to a decline in cognitive function in late life (Bent, 
Rabbit, & Metcalf, 2000; Cukierman, Gerstein, & Williamson, 2005; D. Knopman et al., 
2001; Robbins, Elias, Budge, Brennan, & Elias, 2005). The results of this investigation 
add supporting evidence for its role in predicting MCI as a discrete disease outcome. 
Importantly, diabetes has been identified as a strong predictor of dementia risk (Alonso 
et al., 2009; Lu, Lin, & Kuo, 2009). However not all studies that have explored diabetes 
and MCI have reported that diabetes is a prospective risk factor for MCI (M Kivipelto et 
al., 2001; Solfrizzi et al., 2004). These differences among studies including our own may 
be due to diagnostic criteria used for MCI, which has changed considerably in the last 
twenty years, and varying follow-up periods. 
The presence of an APOE ε4 allele has been associated with poor 
cardiovascular health outcomes and dementia in previous studies (Lahoz et al., 2001; 
Saunders et al., 1993). No relations between APOE genotype and MCI, nor any 
interactions between APOE genotype and the studied cardiovascular risk factors were 
observed. While this finding did not agree with our original hypothesis, findings from the 
literature base on APOE and its association with MCI are mixed. Some previous studies 
have shown that the presence of an ε4 allele is an independent risk factor for MCI (Guo 
et al., 2010; O. L. Lopez et al., 2003). APOE genotype is generally supported as a risk 
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factor for cognitive decline and dementia (Alonso et al., 2009; Laurin et al., 2007) by 
mechanism of exacerbating inflammation associated with cardiovascular risk factors 
(Farrer et al., 1997; Small et al., 2004). Hypertension and cholesterol have been among 
the most studied in the interaction of APOE as it pertains to MCI risk, but to date several 
studies have not supported this relationship (Zambon et al., 2010; Reitz et al., 2007; 
Toro et al., 2014). Larger population based studies are needed to assess the interaction 
of APOE genotype and cardiovascular risk factors with respect to MCI risk, as the 
literature is already quite clear on dementia risk. 
4.1.2 Cardiovascular Risk Factor Scales and Risk Profiles  
 
 In agreement with our hypotheses, an aggregation of cardiovascular risk factors 
dichotomized into the MSLS-CVRFS predicted MCI at 5-year follow up. A higher MSLS 
CVRFS was associated with higher incident MCI. This finding is consistent with both the 
commonly used FRS and the recently developed ASCVD Risk Score, which were also 
associated with incident MCI. While these established risk profiles (FRS and ASCVD) 
have shown great success in predicting risk for CVD, their use in predicting other 
conditions related to cardiovascular health is largely unstudied. In the current study we 
provide evidence that each of these cardiovascular risk scores can be used to predict 
an increased risk of incident MCI. 
 One important contrast between the MSLS-CVRFS and the FRS/ASCVD risk 
scores used for comparison is that the scale developed in this study does not include 
any demographic variables such as age and sex. The intent of the MSLS-CVRFS was 
to focus on cardiovascular risk factors alone, and therefore, we chose to consider age 
as an important demographic covariate rather than as a cardiovascular risk factor. In 
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keeping with theoretical conceptions in advancing age in the life-span psychology 
literature, our conceptualization of chronological age is as a variable representing an 
exposure time in which the prevalence and incidence of CVD is taking place (See 
Schroots & Birren, 1990; Settersten & Mayer, 1997). In this life-span perspective, 
chronological age should be considered an “empty variable” with no force of its own, but 
which encapsulates the combined effect of countless other variables over time. 
Although the FRS and the ASCVD performed slightly better in predicting MCI (See 
Section 3.6.3.) it is important to note that these scales include age, which is arguably 
the single most important risk factor for MCI and clearly the strongest predictor of 
dementia. For reference, the baseline age in our study accounted for an estimated 11% 
of the variance in follow-up MCI when examined separately. This alone was comparable 
to the estimated percent variance explained by the entire FRS and ASCVD scores (See 
Section 3.6.3). Notably, the FRS and ASCVD risk score also include sex as a factor, 
which has been previously reported as an important risk factor, with MCI occurring more 
frequently in men (R. Petersen et al., 2010). These are not criticisms of the risk models 
as these scores were developed to predict CVD with as much accuracy as possible, 
rather than with the intention of elucidating the exact role of certain risk factor 
mechanisms in the development of CVD. In contrast, with the CVRFS we attempted to 
model the contribution of cardiovascular risk factors to MCI risk while controlling for the 
demographic variables included in the other risk scores. Our results do indeed provide 
evidence that cardiovascular risk factors play a role in this risk. When the CVRFS was 
modeled with age and sex included as covariates the total model predicted an 
estimated 15% of the variance in follow-up MCI, which compares favorably to the 
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percent variance accounted for by the other risk scores. Table 13. summarizes model 
R2 values for predicting MCI based on how age was handled as a variable. 
Table 13. Summary comparing Model R2 predicting MCI from Risk Factor Scales 
Scale/Measure 
Age included 
 in scale 
Age included in  
model as 
covariate 
Model R2 
MSLS-CVRFS No No 2% 
MSLS-CVRFS No Yes 15% 
FRS Yes No 7% 
ASCVD Yes No 12% 
Age alone  N/A N/A 11% 
 
 These results of the present study have shown promise in the use of 
cardiovascular risk profiles to predict MCI, despite the fact that these profiles are 
specifically tailored to predict CVD events, with the exception of the MSLS-CVRFS. This 
is not the first study from the MSLS to support the value of risk profiles in predicting 
cognitive impairment; the Framingham Stroke Risk Score was previously shown to 
predict cognitive functioning by Elias and colleagues (2004), albeit the study focused on 
individual cognitive outcomes and not MCI. These findings are important considering 
the large literature base for the role of the cardiovascular system in brain integrity and 
function. Although originally developed to predict CVD outcomes, these results show 
that cardiovascular risk scores can also be utilized to predict MCI risk. Our findings have 
particular relevance to patient treatment strategies because the information used to 
develop these risk scores (BP, cholesterol etc.) is routinely obtained in physician offices 
when a metabolic series is performed. It is clear from the present study that a scale 
employing an aggregation of risk factors is a better predictor of MCI than individual risk 
factors, and this information is easily obtained from physical examination, patient 
history, and metabolic profile.  
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 To our knowledge only one study has developed a risk score specifically tailored 
to predicting MCI risk. Researchers from the Mayo Clinic Study of Aging have recently 
published a risk scoring system specifically for MCI (Pankratz et al., 2015). The 
variables in this scale include both demographic and cardiovascular health variables, 
including sex, years of education, hypertension, and diabetes, among others. The 
model includes little influence from current age, as it is intended to predict future MCI 
incidence based on mid-life cardiovascular health and demographics. As is commonly 
done, age was incorporated in the model as a factor of exposure time to risk factors. 
Although this risk factor profile shows promise emerging from a study that has been 
heavily involved in the development of the construct of MCI, further validation in 
different study populations is necessary.  
One of the issues in all risk factor scales that employ age is that age is a 
powerful predictor of MCI and cognitive performance and can obscure the role of other 
risk factors. Scales employed by epidemiologists employ age from an entirely empirical 
perspective in order to maximize prediction. Our primary scale (MSLS-CVRFS) 
excluded age based on the conceptualization of age as an empty variable in order to 
focus on the contribution of cardiovascular risk factors to MCI risk. As discussed above, 
regardless of whether one includes or excludes age in a risk factor scale, risk factor 
scales combining multiple measures predict MCI better than individual risk factors. 
4.2. Summary 
 
 In this MSLS sample cardiovascular risk factors predicted MCI in a 5-year 
prospective analysis. This included blood pressure, GFR, HDL cholesterol, THCY, 
Diabetes and PWV (cross-sectional). Of these associates GFR and HDL were 
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particularly strong predictors of MCI risk, with higher levels predicting lower MCI 
incidence independent of age, sex, education, and ethnicity. While we expected more 
risk factors to predict MCI it was evident that a combination of risk factors as part of a 
cardiovascular risk factor scale offered better MCI risk prediction. 
The MSLS-CVRFS also predicted MCI risk, and this association was seen with 
adjustment for age, sex, education and ethnicity. Moreover, the CVRFS was linearly 
associated with the cognitive composite scores that were used in MCI diagnosis.  The 
FRS for general CVD risk and the recent ASCVD risk score both predicted incident MCI 
with adjustment for demographic variables that were not included in the score. These 
findings support the role of cardiovascular risk factors in clinically defined cognitive 
impairment with older age, and suggest that risk factor scores have more utility than 
individual risk factors for predicting risk of MCI 
4.3. Mechanisms Underlying Cardiovascular Health and Cognitive Function 
 
The current study did not involve an investigation of potential mechanisms 
underlying the association of cardiovascular risk factors with cognitive functioning. 
However, it is possible to speculate on these mechanisms based on prior research.  
The prevailing theory on how alterations in the cardiovascular system can influence 
cognitive function requires a consideration of the subtypes of cerebrovascular diseases 
which range considerably in type and severity. Of particular interest is the influence of 
the cardiovascular system on major white matter neuronal tracts in the brain. These 
tracts are heavily myelinated neurons responsible for rapid processing speed and 
communication among different brain regions. Advancements in brain imaging 
techniques have allowed for the easy detection of white matter damage or degradation, 
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such as White Matter Hyperintensities (WMH). Manifesting as bright white spots on T2 
weighted MRI images, WMHs are often clinically silent regions of white matter 
degradation possibly due to small vessel diseases. Other microvascular injuries include 
lacunar infarcts and cerebral micro-bleeds which are similarly asymptomatic.  
 White Matter Hyperintensities (also known as Leukoaraiosis) have been related 
to cardiovascular risk factors, cognitive function, and dementia. WMH volume has been 
associated with the Framingham Stroke Risk Profile as well as several individual 
cardiovascular risk factors including hypertension, arterial stiffness, kidney function, and 
diabetes (Fornage et al., 2011; Hughes et al., 2013; Jeerakathil et al., 2004; Khatri et 
al., 2007; Liao et al., 1997; Longstreth et al., 2005; Skoog, 1998; Van Dijk et al., 2004). 
In turn WMHs have also been associated with lowered cognitive performance, with 
executive function impairment commonly seen in patients with high WMH burden (Au, 
Massaro, Wolf, Young, & Beiser, 2006; Breteler et al., 1994; Carmichael et al., 2010; de 
Groot et al., 2001; Longstreth et al., 2005). Larger WMH burden is also seen in AD 
cases, with MCI participants showing WMH levels between those observed in AD and 
CN participants (Yoshita et al., 2006). It is important to note that white matter volume 
changes are considered a normal aspect of aging, with volume gradually increasing 
from birth to midlife, after which volume slowly declines (Kennedy & Raz, 2009). Based 
on the evidence relating cardiovascular risk factors to WMHs independent of age, it is 
reasonable to hypothesize that an increase in cardiovascular risk factors may 
accelerate the lifespan curve of white matter volume and potentially influence cognitive 
deficits and increased dementia risk.  
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 The literature suggests a similar association among cardiovascular risk factors 
with lacunar infarctions and cognitive impairment. Also known as lacunar strokes, these 
cerebrovascular injuries are characterized by small vessel blockages leading to 
subsequent cell death in deep brain regions represented by small cavities on brain 
scans. Like a major acute stroke, lacunar infarctions are associated with an increase in 
cardiovascular risk factors and have been associated with cognitive function and 
dementia (Mungas et al., 2005; Vermeer, Longstreth, & Koudstaal, 2007). Findings from 
the Nun Study demonstrated a 20-fold increase in dementia incidence in brains with AD 
pathology that also had lacunar strokes (Snowdon et al., 1997).  
The small cerebral vessels of the cerebrovascular system are susceptible not 
only to localized disease but also to damaging inputs from the central cardiovascular 
system. These vessels function somewhat differently from other peripheral vessels. 
They are constantly in a state of blood perfusion due to lowered vascular resistance as 
a result of increased vasodilation (O’Rourke & Safar, 2005). This phenomena is in sharp 
contrast to what takes place in peripheral vessels located in the arms for example, that 
have much higher vascular resistance and exhibit more vasoconstriction. While the 
physiology of these cerebral vessels allows for constant blood perfusion to meet the 
large metabolic demands of the brain, it also makes them particularly vulnerable to 
damage caused by high pressure waves resulting from a system that has seen a 
reduction in arterial compliance. Arterial stiffening resulting in higher PWV and pulse 
pressure may be a primary contributor to this damage, even if the reductions in 
compliance occur in the central cardiovascular system and not the cerebral vessels 
themselves, which are often spared from atherosclerotic processes.  
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While there is an abundance of evidence suggesting a mechanistic association 
between cardiovascular risk factors and cognitive functioning by way of small vessel 
diseases and central hemodynamics, there is an additional issue that needs to be 
addressed. If this mechanistic relation is hypothesized, it should stand to reason that 
treatment of the cardiovascular risk factors should lower the extent of cerebrovascular 
injury and therefore improve or prevent cognitive decline including MCI and Dementia. 
The evidence supporting this hypothesis is mixed. Some reviews and studies have 
suggested that early treatment of cardiovascular risk factors like hypertension reduces 
dementia risk (M.F. Elias et al., 2012; Forette et al., 2002). However, most of these 
treatment interventions have been oriented at prevention of cerebrovascular damage 
and cognitive impairment to begin with. Importantly, no studies have shown concrete 
evidence that these outcomes are completely reversible by treating cardiovascular risk 
factors, despite arguments that they are modifiable. Nevertheless the pursuit of viable 
treatment interventions for cognitive impairment associated with cardiovascular health is 
a critical objective in the study of MCI and dementia and should be a large focus of 
future studies. 
 In summary, while we did not perform studies allowing us to identify 
mechanisms in this investigation there is a strong literature base implying the role of 
central cardiovascular risk factors in cognitive performance by means of 
cerebrovascular damage. The MSLS will be unable to pursue mechanistic investigations 
further, but we encourage other studies to consider investigating underlying 
mechanisms relating cardiovascular health to MCI. 
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4.4. Study Limitations and Strengths 
 
4.4.1. Limitations 
 
While the current study provides important new data on cardiovascular risk 
factors in relation to MCI, several limitations should be considered. This study used an 
archival diagnosis of MCI that was derived from a full neuropsychological assessment 
supported by various medical and social assessments. Here we use the term “archival” 
to define a diagnosis that is based on existing data from the MSLS and does not include 
further correspondence with the patient. For compliance with privacy protection and 
approved MSLS human subjects research protocol we are blind to who the patients are. 
Archival diagnosis can be difficult, and care must be taken to apply diagnostic criteria as 
rigidly as possible with all relevant data available. Furthermore, archival diagnosis is 
limited in comparison to direct contact with the individual as would be the case in a clinic 
setting. However, in order to make the diagnosis of MCI as accurate as possible we 
strictly adhered to the primary principles of MCI diagnoses outlined in Section 1.4.2. 
 In accordance with these principles a participant in the MSLS had to exhibit a 
decline from previous cognitive function to a sufficient degree, be free from dementia, 
and be able to function independently in their everyday life. The MSLS includes data 
relevant to all of these principles, and we were therefore able to retrospectively identify 
subjects that fit this well-established MCI profile. Furthermore, a stricter definition for 
cognitive decline was utilized in the current study in order to limit false positive 
diagnoses. This same approach was taken in the Framingham studies of dementia (M F 
Elias et al., 2000). Importantly, the MSLS neuropsychological battery is comprehensive 
and extensive, and therefore, we were also able to consider all possible cognitive 
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decline phenotypes that may represent MCI, including single and multi-domain 
impairment. 
  While seven waves of data have been collected in the MSLS since 1975, the 
current study was limited to a 5-year follow-up period because some cardiovascular risk 
factors of interest (Serum lipids, THCY, GFR) were not available prior to Wave 6 of the 
study (See Section 2.1.). While other MSLS studies, particularly those using blood 
pressure and hypertension as primary predictors, have been able to use longer follow-
up periods, we feel the current 5-year period is necessary because we are specifically 
investigating a mid to late life sample who carry the highest risk for MCI diagnosis. It 
was likewise necessary to maximize the number of cardiovascular risk factors included 
in the study, and Wave 6 of the MSLS has the largest number of risk factors available.  
 The MSLS-CVRFS has some shortcomings related to the fact that we lacked the 
sample size to develop a more sophisticated scale based on continuously distributed 
cardiovascular risk factors (used in prediction models like the FRS and ASCVD risk 
score). Both of these prediction models were based on algorithms derived from large 
datasets. In contrast, in the current study we were restricted to two categories (yes/no) 
based on current diagnostic standards and counted the number of risk factors to create 
our scale. This method essentially weighs each risk factors equally in the scale. This 
method allowed us to consider the role of clinically defined cardiovascular risk 
conditions to MCI at the cost of some recognition for risk factors that may be just above 
or below the clinical cutoff points. The MSLS-CVRFS was developed as a research 
instrument and not a formal psychometric scale, with the intent to study the contribution 
of a combination of cardiovascular risk factors.  
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4.4.2. Strengths  
 
 Despite the limitations discussed above, the current study has a number of 
important strengths. To our knowledge this study is the first to relate a cardiovascular 
risk factor aggregation score to MCI in a prospective design. Additionally, we have 
further validated the use of cardiovascular risk factor algorithms, such as the FRS and 
ASCVD, in the prediction of negative health outcomes. Furthermore, like the 
Framingham risk studies the MSLS sample is a community-based sample with a large 
number of older adults, rather than patients recruited from clinics or in-hospital.  
 While our sample is small relative to large studies like the Framingham Heart 
Studies which often include several thousand participants in an analysis, we have one 
of the largest test batteries in a NIH funded study with 22 cognitive measures (See 
Torres, Elias, Seliger, Davey, & Robbins, 2016).The depth of this cognitive assessment 
is not practical in a large sample typical of an observational study. This extensive 
cognitive battery is invaluable for investigating decreases in cognitive performance and 
formed the basis for our MCI diagnosis. The current study utilized all of the available 
data from the cognitive battery. The analyses in this study were strictly restricted to only 
individuals who had complete cognitive testing data and attended Wave 6 and 7 of the 
MSLS.  
4.5. Future Directions 
 
 MCI has already been established as a clinically defined precursor to dementia. 
Ultimately, its clinical significance is dependent on how well it predicts transition to 
dementia because MCI itself is does not interfere with activities of daily living by 
definition. MCI has met this condition fairly well, albeit different definitions abound. 
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Regardless of various criteria, when a diagnosis of MCI is made reasonably and 
empirically based, it predicts much higher transition rates to dementia than are expected 
in the general population (Larrieu et al., 2002; Petersen et al., 1999; Petersen, 2011). 
Therefore, two transition periods in the assessment of MCI are of critical clinical 
importance: The transition from normal functioning to MCI, and the transition from MCI 
to dementia. 
The current study joins several other studies in providing evidence for the 
important role of cardiovascular risk factors in the transition from normal functioning to 
MCI. While more studies exploring the role of cardiovascular health in this transition are 
needed, the second conversion phase from MCI to dementia also requires investigation. 
More work remains to be done exploring risk factors that may exacerbate the second 
transition rate from MCI to dementia, with particular attention to cardiovascular risk 
factors which may contribute to forms of VaD or mixed vascular-Alzheimer’s pathology 
dementia (Merrill F. Elias & Davey, 2009). There are a few studies that have explored 
this conversion phase, and have provided evidence that certain cardiovascular risk 
factors including APOE ε4 increase the risk for a transition to dementia (Kryscio, 
Schmitt, Salazar, Mendiondo, & Markesbery, 2006). More studies are needed, 
particularly those investigating possible mechanisms such as arteriosclerosis and 
cerebrovascular disease. 
Differential diagnosis of MCI should remain a primary goal in epidemiological 
studies assessing MCI and dementia risk. These diagnoses can be difficult to make 
however as cognitive phenotypes displayed in patients with MCI can be incredibly 
heterogeneous (See section 1.4.). However if these different forms of MCI can be 
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accurately mapped onto the forms of dementia they specifically predict (e.g. Amnestic 
Single Domain MCI -> Alzheimer’s Disease) it will vastly improve the clinical use of an 
MCI diagnosis because interventions can be tailored to the specific form of dementia 
that the patient is at risk of developing. This is particularly relevant for identifying forms 
of cognitive impairment that may predict mixed forms of vascular and Alzheimer’s 
pathology as these are underrepresented in a field biased towards AD prediction 
(Sullivan & Elias, 2016). 
4.6. Conclusion 
 
The current study contributes to identifying risk factors for MCI, which should be 
a critical epidemiological goal in the effort to combat increasing dementia rates 
worldwide. Dementia is an irreversible condition and efforts to address this disease 
should focus on prevention and delaying onset. Of particular value in this effort will be 
the identification of modifiable risk factors for which treatment may reduce risk of 
abnormal or accelerated cognitive decline with age. Cardiovascular risk factors have 
been associated with cognitive decline and dementia (Waldstein & Elias, 2015), and the 
current study suggests that they may predict prodromal states of dementia including 
MCI. Just as patients are advised to treat cardiovascular risk factors in an effort to 
prevent CVD, the risk of dementia associated with an unhealthy cardiovascular profile 
should also be considered.  
We consider each objective and hypothesis presented in Section 1.7. in turn. 
While we did see that individual cardiovascular risk factors could predict MCI incidence, 
most of these associations were lost with control for the basic covariate model. 
However, this was not the case with GFR and HDL cholesterol, which were associated 
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with lower MCI risk. Furthermore, diabetes was associated with an increased MCI 
incidence. Contrary to our hypothesis, no moderating effect of APOE ε4 allele was 
observed with any risk factor. In agreement with our hypothesis, an aggregation of 
cardiovascular risk factors, reflected in our CVRFS, predicted higher risk of MCI. Two 
recommended cardiovascular risk factor algorithms, the FRS and ASCVD risk score, 
also predicted higher risk of MCI. As originally hypothesized the FRS and ASCVD 
performed better in predicting MCI than the CVRFS, likely because the former two risk 
scores include age. Lastly, in agreement with our final hypothesis the CVRFS also 
predicted continuously distributed cognitive performance measures from the MSLS 
cognitive battery. 
The present study has many implications for predicting MCI using cardiovascular 
risk factors. Among the individual risk factors we studied, GFR, HDL cholesterol, and 
diabetes were particularly strong predictors of MCI. However, using a combination of 
multiple risk factors may prove more useful in predicting MCI risk than any single risk 
factor, even when age is not accounted for. Patients often come to physicians with 
multiple cardiovascular risk factors, and these individuals may be more vulnerable to 
MCI and conversion to Dementia. We find that our MSLS-CVRFS, the scale developed 
in this study, was more successful in predicting individual cognitive outcomes measured 
continuously, but the larger importance of this study is in presenting evidence for 
predicting MCI as a clinically defined disease that demands a yes/no treatment decision 
from physicians. Predicting this risk is especially useful when it can identify MCI so that 
interventions can occur long before dementia occurs in an effort to counteract long 
prodromal phase of dementia. We strongly recommend that future studies associating 
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cardiovascular risk factor aggregation and individual risk factors with MCI should identify 
MCI subtypes (amnestic single domain, non-amnestic single domain etc.) in an effort to 
develop different risk profiles predicting different types of dementia (AD, VaD, Mixed).  
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APPENDIX A: FRAMINGHAM RISK SCORE CALCULATION 
 
Table 14. FRS Calculation for Women 
Points Age SBP (Untreated) SBP(Treated) TC HDL Smoker Diabetic 
-3  < 120      
-2     60+   
-1   <120  50-59   
0 30-34 120-129  <160 45-49 No No 
1  130-139  160-199 35-44   
2 35-39 140-149 120-129  <35   
3   130-139 200-239  Yes  
4 40-44 150-159  240-279   Yes 
5 45-49 160+  280+    
6   150-159     
7 50-54  160+     
8 55-59       
9 60-64       
10 65-69       
11 70-74       
12 75+             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tables and scoring adapted from D’Agostino et al. 2008 
Table 15. FRS Calculation for Men 
Points Age SBP (Untreated) SBP(Treated) TC HDL Smoker Diabetic 
-2  <120   60+   
-1     50-59   
0 30-34 120-129 <120 <160 45-49 No No 
1  130-139  160-199 35-44   
2 35-39 140-159 120-129 200-239 <35   
3  160+ 130-139 240-279   Yes 
4   140-159 280+  Yes  
5 40-44  160+     
6 45-49       
7        
8 50-54       
9        
10 55-59       
11 60-64       
12 65-69       
13        
14 70-74       
15 75+             
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APPENDIX B: ARTERIOSCLEROTIC CARDIOVASCULAR DISEASE RISK SCORE 
CALCULATION 
 
Method: A coefficient sum C is calculated for a patient with a different algorithm based 
on sex, ethnicity (White vs African American Only), and hypertensive treatment status 
(Treated vs Untreated). This coefficient sum is then converted to a 10-year risk 
percentage in a second equation including parameters based on average values 
(baseline survival rate and average coefficient sum) for that patient’s sex and ethnicity.  
 
Coefficient Sum Calculation (C) 
Men 
White 
Untreated: (ln(Age) * 12.344) + (ln(TC) * 11.853) + ((ln(Age * ln(TC)) * -2.664) + (ln(HDL) * - 
7.990) + ((ln(Age) * ln(HDL)) * 1.769) + (ln(SBP) * 1.764) + (Smoker * 7.837) + ((ln(Age) * 
Smoker) * -1.795) + (Diabetes * .658) = C 
 
Treated: (ln(Age) * 12.344) + (ln(TC) * 11.853) + ((ln(Age * ln(TC)) * -2.664) + (ln(HDL) * - 
7.990) + ((ln(Age) * ln(HDL)) * 1.769) + (ln(SBP) * 1.797) + (Smoker * 7.837) + ((ln(Age) * 
Smoker) * -1.795) + (Diabetes * .658) = C 
 
African American 
Untreated: (ln(Age) * 2.469) + (ln(TC) * .302) + (ln(HDL) * -.307) + (ln(SBP) * 1.809) + 
(Smoker * .549) + (Diabetes * .645) = C 
 
Treated: (ln(Age) * 2.469) + (ln(TC) * .302) + (ln(HDL) * -.307) + (ln(SBP) * 1.916) + (Smoker * 
.549) + (Diabetes * .645) = C 
 
Women 
White 
Untreated: (ln(Age) * - 29.799) + ((ln(Age) * ln(Age)) * 4.884) + (ln(TC) * 13.540) + ((ln(Age) * 
ln(TC)) * -3.114) + (ln(HDL) * -13.578) + ((ln(Age) * ln(HDL)) * 3.149) + (ln(SBP) * 1.957) + 
(Smoker * 7.574) + ((ln(Age) * Smoker) * -1.665) + (Diabetes * .661) = C 
 
Treated: (ln(Age) * - 29.799) + ((ln(Age) * ln(Age)) * 4.884) + (ln(TC) * 13.540) + ((ln(Age) * 
ln(TC)) * -3.114) + (ln(HDL) * -13.578) + ((ln(Age) * ln(HDL)) * 3.149) + (ln(SBP) * 2.019) + 
(Smoker * 7.574) + ((ln(Age) * Smoker) * -1.665) + (Diabetes * .661) = C 
 
African American 
Untreated: (ln(Age) * 17.114) + (ln(TC) * .940) + (ln(HDL) * -18.920) + ((ln(Age) * ln(HDL)) * 
4.475) + (ln(SBP) * 27.820) + ((ln(Age) * ln(SBP)) * -6.087) + (Smoker * .691) + (Diabetes * .874) 
= C 
 
Treated: (ln(Age) * 17.114) + (ln(TC) * .940) + (ln(HDL) * -18.920) + ((ln(Age) * ln(HDL)) * 
4.475) + (ln(SBP) * 29.291) + ((ln(Age) * ln(SBP)) * -6.432) + (Smoker * .691) + (Diabetes * .874) 
= C 
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10-Year ASCVD Risk Percentage Calculation  
Basic Formula: 
 1 – Baseline Survival Ratee^(Patient Coefficient Sum – Average Coefficient Sum) = % Risk  
Men 
White 
 1 – 0.9144e^(C – 61.68) = % Risk 
 
African American 
 1 – 0.8954e^(C – 19.54) = % Risk 
 
Women 
White 
 1 – 0.9665e^(C + 29.18) = % Risk 
 
African American 
 1 – 0.9533e^(C – 86.61) = % Risk  
 
Algorithm adapted from Goff et al. (2014) 
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APPENDIX C: MSLS COGNITIVE BATTERY AND FACTOR ANALYZED COGNITIVE 
DOMAINS 
 
Table 16. Descriptions of Cognitive Tests for Each Cognitive Domain  
Composite/  
Tests included 
Cognitive Ability Measured 
Verbal Episodic Memory  
 Logical Memory-Immediate Recall a Immediate memory, verbal 
 Logical Memory-Delayed Recall a Delayed Memory, verbal 
 Hopkins Verbal Learning Test Verbal learning and memory 
Visual-Spatial Organization/Memory  
 Visual Reproductions-Immediate Recall a Immediate recall, visual memory and visual spatial problem solving 
 Visual Reproductions-Delayed Recall a Delayed recall, visual memory and visual spatial problem solving 
 Matrix Reasoning b Abstract reasoning and pattern recognition  
 Block Design c Visual-spatial perception, organization 
 Object Assembly c Speed of visual-spatial organization  
 Hooper Visual Organization Visual-spatial organization, some demands on executive function 
Scanning and Tracking  
 Trail Making A d Visual scanning and tracking; concentration and attention 
 Trail Making B d Trails A plus demands on executive function abilities 
 Digit Symbol Substitution c Psychomotor performance 
 Symbol Search b Visual processing speed 
Working Memory  
 Digit Span Forward c Attention and concentration 
 Digit Span Backward c Attention, concentration, and working memory 
 Letter-Number Sequence b Information processing while holding information in memory 
 Controlled Oral Word Associations Verbal fluency and executive function 
Executive Function  
 Trail Making B d Trails A plus demands on executive function abilities 
 Controlled Oral Word Associations Verbal fluency and executive function 
a Origin Wechsler Memory Scale-Revised 
b Origin Wechsler Adult Intelligence Scale III 
c Origin Wechsler Adult Intelligence Scale  
d Origin Halstead-Reitan Neuropsychological Test Battery 
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APPENDIX D: ADDITIONAL FIGURES FOR CVRFS AND COGNITIVE COMPOSITE 
ANALYSES 
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Figure 14. CVRFS Score and Verbal Memory  
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Figure 15. CVRFS Score and Visual Organization/Memory  
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Figure 16. CVRFS Score and Scanning/Tracking  
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Figure 17. CVRFS Score and Working Memory   
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Figure 18. CVRFS Score and Executive Function   
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